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 1 
General Introduction 
 
 
Rational and experimental goals 
 
Hemolytic uremic syndrome (HUS), a systemic complication of Shiga toxin-
producing Escherichia coli (STEC) infection, is the number one cause of renal failure in 
children in the United States [1-3].  At present, there is no known method to predict 
which patients with STEC infection will develop HUS and no effective treatment for the 
disorder once it is diagnosed.  One of the primary barriers inhibiting development of an 
adequate therapy and/or preventative is an insufficient understanding of the intricate 
pathogenic cascade.  It is known that Shiga toxin (Stx) is produced locally within the 
gastrointestinal tract, is absorbed into the systemic circulation by a yet undefined 
mechanism, binds to vascular endothelial cells expressing the Stx receptor [4-6].  Stx is 
then internalized within the endothelial cell and interrupts protein synthesis, causing cell 
death.   This endothelial cell injury causes microthrombi formation in key target organs 
(kidney, brain, colon) leading to the characteristic clinical triad of HUS: 
microangiopathic hemolytic anemia, thrombocytopenia, and acute renal damage [7].  
Although Stx is widely presumed to be the principal mediator of HUS, proinflammatory 
cytokines have been repeatedly implicated as substantial contributors to disease 
development.  Stx induces cytokine production in a variety of cell types in vitro, and 
cytokines, in turn, greatly increase the sensitivity of endothelial cells to Stx [8-11].  
Several clinical studies have identified increased proinflammatory cytokines in patients 
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with HUS compared to those with STEC-induced diarrhea alone [12-15].  A more 
complete understanding of both toxin transport mechanisms and cytokine responses 
during HUS would aid in the development of treatment modalities; however, both the 
primary mode for toxin transport in vivo and the stimulus for cytokine alterations seen in 
HUS remain uncharacterized.  Specifically, the role of Stx production and dissemination 
in proinflammatory cytokine alterations observed in clinically-affected patients has not 
been established.  The goals of the studies outlined in this thesis were to: 1) clarify the 
role of Stx in modulating inflammation during STEC infection 2) identify specific 
interactions between Stx and neutrophils to assess the potential role of this leukocyte in 
Stx transport during STEC infection and 3) assess the efficacy of an oral Stx-binding 
agent at preventing systemic disease following STEC inoculation.  To accomplish these 
goals, in vitro experiments, as well as in vivo experiments in an animal model of STEC 
infection, were used.  The animal model chosen for the in vivo experiments was edema 
disease of swine, a naturally occurring STEC disease of weaned swine caused by host-
adapted strains of E. coli.  Experimentally infected swine are colonized in the intestinal 
tract and approximately 30% of individuals develop clinical edema disease manifested by 
neurological symptoms due to systemic Shiga toxemia [16-18].  Edema disease has been 
used as an animal model to study HUS based on the similar pathogenesis between the 
two diseases [18].   
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Dissertation organization 
 
This dissertation is composed of an introduction and review of the literature 
(Chapter 1) followed by three separate manuscripts to be submitted to peer reviewed 
journals (Chapters 2-4).  A general conclusion is given in Chapter 5.  References are cited 
at the conclusion of each chapter.  The following is a summary of author’s roles for each 
of the three manuscripts included in Chapters 2-4: 
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  Shannon J. Hostetter: Graduate student, primary researched and author. 
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  Adrienne Paton: Collaborator. 
  Nancy A. Cornick: Associate professor and corresponding author. 
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  Shannon J. Hostetter: Graduate student, primary researcher and author. 
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  Nancy A. Cornick: Associate professor and corresponding author. 
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Chapter 1: Literature review 
 
Escherichia coli are Gram negative facultative anaerobes of the family 
Enterobacteriaceae and are a major component of the normal intestinal flora in many 
species.  Although most E. coli are non-pathogenic, some have acquired virulence 
attributes and are capable of causing severe disease in a variety of hosts.  STEC (Shiga 
toxin-producing Escherichia coli) produce a potent cytotoxin, known as Shiga toxin 
(a.k.a. verocytotoxin, Shiga-like toxin), that inhibits protein synthesis in susceptible host 
cells (105).  Serotyping is a common way to characterize STEC strains, and is based on 
the O antigen (somatic antigen) and H antigen (flagellar antigen).  The most common 
serotype associated with human disease is O157:H7 (55, 144).   
STEC infection in human beings is primarily a zoonotic disease, and ruminants 
are considered the major animal reservoir, although pigs and other animals also may 
serve as carriers (55).   The primary site of intestinal colonization of STEC in cattle is the 
terminal rectal mucosa and rectoanal junction (23, 106, 128).   Some cattle are known to 
yield far greater numbers of O157:H7 than most, and are referred to as “super-shedders.”  
They are defined as shedding greater than or equal to 104 colony forming units (CFU) per 
gram of feces, and epidemiologic evidence suggests they are critical sources of both 
parallel transmission within the reservoir, as well as zoonotic transmission (21).  Human 
exposure to STEC can come from multiple sources, including ingestion of contaminated 
fruits and vegetables, undercooked ground beef, unpasteurized apple cider or milk, 
salami, contact with livestock, and parallel transmission from infected individuals (21).  
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The infectious dose of STEC is remarkably low (50 CFU or less), and this contributes to 
the virulence of the organism (144).  
 
Shiga toxin-producing Escherichia coli infections in human beings. 
 
Shiga-toxin producing strains of Escherichia coli (STEC) are responsible for 
approximately 110,000 cases of food borne illness annually in the U.S. and are a major 
cause of hemorrhaghic colitis (95).  STEC strains capable of causing severe disease in 
human beings are also classified as enterohemorrhagic Escherichia coli (EHEC), one of 
the pathotypes of E. coli that cause enteric disease.  A small percentage of patients (3-
15%) with diarrhea secondary to STEC infection develop a systemic and potentially fatal 
complication known as hemolytic uremic syndrome (HUS), characterized by the triad of 
microangiopathic hemolytic anemia, thrombocytopenia, and acute renal damage (68, 
122).  HUS is primarily mediated through Shiga toxin (Stx) dissemination and is reported 
to be the most common cause of acute renal failure in children (95, 133).  Although renal 
lesions (microvascular thrombopathy in glomeruli) are the histologic hallmark of HUS, 
death of HUS patients is usually attributed to similar vascular lesions in the brain rather 
than the kidney (137, 138).  HUS can be broadly classified into two main types: diarrhea 
associated (D+HUS) and diarrhea negative HUS (D-HUS).  D-HUS is less common than 
D+HUS, making up approximately 10% of total reported cases of HUS.  D-HUS can 
occur in association with a variety of conditions, including complement and coagulation 
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abnormalities, antiphospholipid syndrome, pregnancy, and human immunodeficiency 
virus infection (7, 89).  The vast majority of D+HUS cases are caused by STEC infection; 
however,  Shigella dysentariae type 1 infection is the primary cause of HUS in some 
developing countries, and HUS also occurs as a rare sequelae to Streptococcus 
pneumoniae infection in children (27, 89).   
STEC were initially implicated as the cause of diarrhea-associated HUS by 
Karmali and colleagues back in the mid-1980’s  (68).  STEC that produce Shiga toxin 
(Stx) 1, Stx2, or both toxins have been associated with HUS development; however, both 
epidemiologic evidence and work with animal models show that strains producing Stx2 
only are more likely to cause severe disease (34, 43, 124, 151).  Characterization of 
STEC isolates from patients with HUS suggest that E. coli O157:H7 is the predominant 
strain recovered in the United States (4, 9).  HUS is more prevalent in children under the 
age of 10 and the elderly, and it remains the leading cause of renal failure in children in 
the U.S. (39, 52, 67).  At present, there is no known method to predict which patients 
with diarrhea caused by STEC will develop HUS, and no known treatment for the 
disorder once it is diagnosed.  Clinically, HUS secondary to STEC infection is preceded 
by a prodromal diarrheal phase that typically lasts approximately 7 days.  In most 
patients, the diarrhea progresses to bloody diarrhea within a few days (144).  Although it 
is based somewhat on both bacterial serotype and patient age, up to 15% of individuals 
with STEC infection will develop HUS (data for serotype O157:H7) (144, 172).  Patients 
who develop HUS are currently managed with supportive therapy only (160).  Although 
recent research on HUS has identified some elements in the pathogenesis of the disease 
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and certain risk factors for disease development, many details of the pathogenic cascade 
beginning with STEC ingestion and culminating in HUS remain unknown.   
 
Virulence attributes of STEC causing human disease 
 
Locus of enterocyte effacement and intimin 
 
 The locus of enterocytes effacement (LEE) is a chromosomally associated 
pathogenicity island encoding the proteins responsible for attaching and effacing lesions 
(A/E) on the intestinal mucosa (93).  A/E lesions are characterized by the loss of apical 
villi on enterocytes with rearrangement of the cytoskeleton leading to the formation of an 
intimate association between bacterium and enterocyte forming a classic pedestal 
appearance (105).  The formation of A/E lesions is prototypical of another E. coli 
pathotype, the enteropathogenic E. coli (EPEC); however, many STEC strains 
responsible for human disease also possess LEE and form A/E lesions experimentally 
(105).  Five polycistronic operons make up LEE, designated LEE1-LEE5.  The products 
of LEE include a Type III secretion system, intimin, and secreted effector proteins such 
as Tir, EspF, EspG, and EspH (55).  Intimin, an outer membrane protein adhesin, is 
encoded by eae and is primarily responsible for the intimate attachment of EPEC and 
STEC to the enterocyte.  Multiple subtypes of intimin have been described, and this 
heterogeneity may contribute to some variability in binding to various eukaryotic cell 
receptors (46). Regardless of subtype, however, the primary host cell receptor for intimin, 
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Tir, is actually produced by the bacterium and translocated into the host cell through the 
Type III secretion system also encoded on LEE.  Additionally, there is evidence that 
some intimin subtypes bind to native host receptors.  Intimin-α of EPEC binding to β1 
integrins  has been identified, and several intimin subtypes have the ability to bind 
nucleolin (44, 140).  Moreover, Tir, nucleolin, and β1 integrins were all identified in 
areas of O157:H7 adherence to enterocytes using immunohistochemistry in bovine and 
porcine intestine (140).   
The majority of STEC strains pathogenic to human beings are eae-positive, and 
eae has been identified as a risk factor for HUS development (169).  Regulation of 
expression of LEE in EPEC is mediated through LEE encoded regulators Per and Ler, as 
well as more global regulators such as H-NS and quorum sensing regulators (72, 139).   
STEC do not appear to possess a Per homologue; however, it is suggested that Ler plays 
a role in gene regulation of LEE in O157 STEC, and may be involved in intimin-
independent adherence (113).  Despite the presumed importance of LEE in the 
pathogenesis of STEC infection, a number of eae-negative STEC strains have been 
associated with outbreaks of hemorrhagic colitis and HUS, most notably STEC 
O113:H21 (108).  Currently, little is known about how eae-negative STEC strains 
mediate specific adherence to enterocytes during colonization.   
 
 
 
 
 11 
Toxins 
 Shiga toxin 
 
 Shiga toxin is the principal mediator of diarrhea-associated HUS.  Stx of E. coli 
were first described in the late 1970’s when it was noted that filtrates from certain E. coli 
strains were toxic to Vero cells (derived from the kidney of African green monkeys) in 
vitro (77).   They were originally designated verocytotoxins, and were subsequently 
recognized for their structural and functional similarity to Shiga toxin of Shigella 
dysenteriae type I (111).   Two main subgroups of STEC Stx are recognized, Stx1 and 
Stx2 (112, 152).  There are several variants described for Stx2, including Stx2e, the toxin 
principal of porcine edema disease.  Stx1 is 99% similar to Shiga toxin of Shigella 
dysenteriae type I, yet Stx2 shares only ~56% amino acid homology with Stx1 (143, 
161).  Stx1 and Stx2 are phage-encoded, although Stx1 may also be chromosomally 
encoded (110, 142).  Stx are classic AB5 toxins, composed of a single enzymatic A 
subunit non-covalently associated with  5 glycolipid-binding B subunits (122).  Both Stx1 
and Stx2, as well as most Stx2 variants, preferentially recognize globotriaosylceramide 
(Gb3) on the surface of cells; however, differences in receptor affinity between Stx1 and 
Stx2 have been described (104).  Following specific binding of Stx to Gb3, the complex 
is internalized via clathrin-coated pit mediated endocytosis.  The toxin then travels via 
retrograde transport to the Golgi and then the endoplasmic reticulum, during which time 
the A subunit is cleaved to form an active N-glycosidase.  This active enzyme functions 
in the cytosol to remove an adenine residue on the 28S rRNA, thereby rendering it 
inactive and interrupting protein synthesis (174). 
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 Cytolethal distending toxin 
 
 Cytolethal distending toxin (CDT) was named for the observation that it induced 
cell swelling with subsequent death in certain cell lines (65).  It was later discovered that 
CDT induced cell cycle arrest at the G1 or G2 
 Subtilase toxin (SubAB) of Escherichia coli was initially described in serotype 
O113:H21 as the prototype of a novel family of AB
phase.  CDT is not unique to E. coli, and 
has been described in numerous other pathogens including Helicobacter spp. and Shigella 
spp. (125).  The CDT holotoxin is composed of three different proteins encoded by 
adjacent genes (cdtA, cdtB, cdtC).  Of these proteins, CdtB appears to be enzymatically 
active and cleaves host DNA to promote the cell cycle effects.  Multiple CDT alleles 
exist for E. coli (63). There is some debate as to the significance of CDT in STEC 
pathogens causing human disease, especially since many of the human isolates producing 
Stx are negative for CDT, and the vast majority of O157:H7 strains analyzed likewise 
lack CDT (10).    However, many non-motile O157 strains, as well as non-O157 STEC, 
possess cdt.  Additionally, one of the more recently described CDT proteins, CDT-V, was 
found to cause death in multiple endothelial cell lines in vitro, raising the possibility that 
CDT might contribute to vascular pathology in STEC infection (12). 
 
 Subtilase toxin 
 
5 toxins in 2004 (119).   The toxin 
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was more cytotoxic to Vero cells than Shiga toxin, and the enzymatic A subunit 
contained a “catalytic triad” denoting its similarity to subtilase serine proteases.  The B 
binding pentamer showed affinity for GM2 ganglioside.  Subtilase toxin was found to be 
plasmid encoded by two genes (subA and subB) which were identified in approximately 
50% of the 60 additional STEC strains tested.  Parenteral administration of 200 ng of 
purified toxin was lethal for mice.  The mice exhibited neurological signs before death 
and had histologic lesions consisting of microvascular thrombosis and necrosis in 
multiple organs (brain, kidney, and liver).  The authors proposed that these histologic 
lesions were suggestive of endothelial cell injury, and that Subtilase toxin may contribute 
to the characteristic vascular lesions of HUS, particularly in cases involving stx-negative 
E. coli strains.  
 In an eloquent follow up study, the authors determined the mechanism of action 
for SubAB using proteomic analysis of Vero cells exposed to either SubAB or an inactive 
SubAB mutant (116).  Using this analysis, the cellular target of SubAB was determined 
to be the endoplasmic reticulum (ER) chaperone BiP.  BiP has multiple functions that are 
essential for eukaryotic cell survival, including serving as a master ER regulator, 
directing misfolded proteins to the proteosome and assisting proper folding of secreted 
proteins.  Cleavage by SubAB renders BiP inactive, thereby inducing cell death.  The 
specificity of SubAB for BiP was also confirmed in vivo using the mouse model of 
SubAB toxicity and assessing BiP integrity in liver tissue with SDS-PAGE and western 
blot analysis (116).  Intracellular trafficking of SubAB to the ER was clathrin-dependent 
and appeared to be similar to other AB5 toxins (31).    
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Proteases 
 
 StcE  
 In 2002, Welch et. al. described the function of a previously undescribed protein 
encoded on the virulence plasmid pO157.  Having noted that O157:H7 was capable of 
aggregating Jurkat cells in vitro, and that this property was conferred on pO157, the 
investigators used site directed mutagenesis to identify the specific gene responsible for 
this cytopathic effect.  When the protein was expressed in vitro, it was found to be a zinc 
metalloprotease that specifically cleaved the serine protease inhibitor C1 esterase 
inhibitor (C1-INH).  C1-INH plays a critical role in both inflammation and coagulation 
by inhibiting the classical and mannose-binding complement cascades, as well Factor 
XIIa and XIa.  The protease was named StcE, was speculated to be secreted by type II 
secretion system, and analysis of several O157:H7 isolates revealed the presence of stcE.  
Additionally, StcE secretion was enhanced by expression of the LEE-regulator Ler (173).  
Interestingly, a later study identified that StcE actively recruited C1-INH to the cell 
membrane.  Although StcE specifically cleaved C1-INH, the functional ability of C1-
INH to cleave its substrate and thereby inhibit the classical complement was maintained, 
leading the authors to speculate that StcE may function to actively reduce inflammation 
at the site of colonization (80).  Later studies identified a role for StcE in the intimate 
adherence of O157:H7 to HEp-2 cells, putatively via the active cleavage of glycoproteins 
on the host cell surface (53).  Finally, an additional substrate for StcE was recently 
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identified, mucin MUC7, and its activity as a mucinase in addition to protease was 
confirmed (53). 
 
 EspP 
 Escherichia coli secreted protein P (EspP) is a plasmid-encoded serine protease 
autotransporter found in both virulent and non-virulent STEC strains.  Recently, 
Brockmeyer et. al. identified several different subtypes of EspP in STEC, denoted EspPα, 
β, γ, and δ.  These subtypes possessed differing proteolytic activity and distribution 
amongst the STEC strains examined (17).  More recently, the prevalence of espP 
amongst strains associated with human disease was assessed.  Twelve strains from HUS 
patients were examined, five of these were espP positive, and all five were subtype α.  
Additional analysis of STEC strains causing bloody diarrhea also revealed the majority 
were espP positive, and most of these were subtype α (73).  Although the exact role of 
EspP in STEC pathogenesis remains to be determined, these studies suggest further 
investigations into its role as a putative STEC virulence factor are warranted.   
 
Fimbrial adhesins 
 
Although intimin is by far the most researched and best characterized adherence 
factor for STEC, clearly other adhesins play a role in some, if not all, STEC strains, 
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particularly since numerous eae-negative strains have been associated with human 
disease.  Intimin-independent adherence could potentially be mediated by fimbrial 
adhesins, non-fimbrial adhesins, or a combination thereof.  Several fimbrial adhesins 
have been described in STEC and some are suspected to have a substantial role in STEC 
pathogenesis (85).  Long polar fimbriae (Lpf) similar to that of Salmonella enterica 
serovar Typhimurium have been identified in STEC (155).  Several Lpf variants have 
been identified, and some appear to facilitate adhesion of STEC strain O113:H21 to 
epithelial cells in vitro (35).  In animal models, Lpf contributes to colonization of 
O157:H7 in both sheep and pigs (66).  Additionally, the gene encoding LpfA has been 
identified in numerous eae-negative STEC, and is theorized to be an key adhesin in these 
strains (114). An additional fimbrial adhesin that may play a role in STEC infection is 
Sfp, which has been identified in some non-motile O157 and O165:H25 strains (11).  
These fimbriae were involved in adherence of O157:NM to intestinal epithelial cells in 
vitro and were identified as a putative virulence attribute for these strains (103).  Finally, 
a newly identified fimbrial adherence factor, E. coli common pilus (ECP), is expressed in 
most EHEC strains studied thus far.  Isogenic ecpA mutants had decreased adherence to 
cultured epithelial cells, and ultrastructural data suggests these adhesins form numerous 
attachments to epithelial cells, suggesting ECP plays a role in EHEC adherence to host 
epithelium (127).   
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Non-fimbrial adhesins 
 
Additionally, a number of non-fimbrial adhesins have received attention as 
putative virulence factors in STEC, particularly those strains that are LEE-negative.  
EHEC factor for adherence (Efa1) adhesin is important in colonization of bovine intestine 
by O111 STEC and mediates adherence to Chinese hamster ovary cells in vitro (79, 141).  
A homologue of Efa1, ToxB, is another purported non-fimbrial adhesin for STEC.  ToxB 
is encoded on pO157 virulence plasmid, and toxB mutants exhibit decreased adherence to 
epithelial cells in vitro.  ToxB’s role in adherence may not be direct, however, as it is 
known to modulate effectors of LEE and can contribute to adherence indirectly in this 
manner (145).   STEC autoagglutinating adhesin (Saa) is a plasmid-encoded non-fimbiral 
adhesin that was first described by Paton et. al. in LEE-negative STEC isolates 
pathogenic to humans (120).  Saa helped mediate attachment of STEC to HEp-2 cells in 
vitro, and a comparison between bovine and human STEC strains found a higher 
prevalence in bovine strains, leading the authors to theorize that it may be an important 
factor in colonization of cattle (64, 120).  Some additional proteins that may be involved 
in adherence include OmpA, Iha, and Cah (155).    
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Flagellin 
 
 Flagella are complex organelles which function primarily in motility, although 
they also function as adhesins and are important antigens in host immune responses.  
They appear to be important in the pathogenesis of STEC infections for several reasons.  
Firstly, flagella contribute to STEC adherence and colonization of the intestinal 
epithelium.  In a chick model of EHEC infection, flagella are important for persistent 
colonization (8, 78).  The importance of H7 flagellum in intestinal adherence in the 
bovine, the primary reservoir host for STEC, was further exemplified recently.  
Colonization of rectal epithelial cells with either a fliCH7 mutant or wild type blocked 
with specific anti-H7 antibody was significantly less than that of wild type (3).   
Furthermore, colonization of O157:H7 in the bovine was inhibited by immunization with 
H7 flagellin (94).   Secondly, flagellins are potent inducers of chemokine expression in 
vitro, and appear to play a role in host immune responses to STEC.  IL-8, a chemokine 
that promotes neutrophil recruitment and chemotaxis, and CCL20 (MIP3A), a chemokine 
promoting chemotaxis of lymphocytes and dendritic cells, are both upregulated and 
secreted by cultured intestinal epithelial cells in response to H flagellin (49).   Finally, 
signaling through TLR5 in colonic epithelial cells in response to H7 flagellin induced 
chemokine expression (176). 
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Lipopolysaccharide 
 
Lipopolysaccharide (LPS) is a major structural component of the cell wall of 
Gram negative bacteria.  In the host, LPS from pathogenic bacteria is a well know trigger 
of innate and adaptive immune responses and a major inducer of inflammation.  LPS is a 
polyclonal mitogen, inducing proliferation of both B and T lymphocytes.  Although 
bacteremia is not considered a feature of STEC infection in human beings, LPS antigens 
can circulate bound to plasma LPS-binding protein (LBP), leukocyte receptors such as 
CD-14, and have even been shown to bind platelets.  LPS bound to LBP and CD14 forms 
a complex capable of triggering innate immune responses through TLR-4 signaling, 
including production of proinflammatory cytokines like TNF-α.  Antibodies against O157 
LPS were consistently identified in HUS patients, and thus LPS is likely to contribute to 
the proinflammatory cytokine response observed in HUS patients (20).  Additionally, 
LPS may promote intestinal colonization of STEC.  LPS-specific antibodies were able to 
prevent adherence of O157 and O111 to the human intestinal epithelial cell line Henle 
407 in vitro (121).   O antigen also may promote colonization of the bovine terminal 
rectal mucosa by O157:H7 (134).   
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Shiga toxin dissemination in the pathogenesis of the hemolytic uremic syndrome. 
 
Following colonization of STEC, Stx are produced locally within the intestine, 
then cross the intestinal mucosa and vascular endothelium via a yet undefined mechanism 
to gain access to the bloodstream.  It has been shown in tissue culture systems that 
biologically active Stx can cross intestinal epithelial cells, and that neutrophil 
transmigration across epithelial monolayers enhances Stx translocation (1, 58).   Once the 
toxin reaches the blood, it binds globotriaosylceramide (Gb3
 Several years ago, the first in a series of publications appeared implicating 
peripheral blood neutrophils in the dissemination of Shiga toxin in vivo.  In this study, 
Stx1 was incubated with human whole blood and bound exclusively to 
polymorphonuclear leukocytes.  Neutrophil-bound Stx1 was readily transferred to 
cultured human microvascular endothelial cells and led to cell death via inhibition of 
) on the surface of vascular 
endothelial cells in key target organs (kidney, brain) and is internalized (62).  Toxin 
internalization within endothelial cells results in inhibition of protein synthesis, leading to 
cell death (45).   How Stx is transported in the bloodstream has been debated, and 
although Stx1 and/or Stx2 binding to erythrocytes, platelets, and monocytes has been 
described, it is currently presumed that neutrophils serve as the primary carriers of the 
toxins in the bloodstream.   
 
Role of neutrophils 
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protein synthesis.  Using radiolabeled Stx1, binding studies showed the neutrophil 
receptor bound Stx1 less avidly (approximately 100-fold) than the native Stx receptor on 
vascular endothelial cells, globotriaosylceramide.  The authors theorized that this was the 
mechanism for Stx reaching the renal endothelium from the site of production in the 
colon (147).  Subsequently, the same group was able to detect Stx2 in the systemic 
circulation of patients with HUS.  In this study, 9 out of 10 HUS patients examined had 
Stx2 bound to neutrophils that was detected using indirect immunofluorescence and flow 
cytometry (148).  These same techniques were then used to screen the peripheral blood of 
other members in the households of HUS patients for subclinical STEC infection.  The 
sensitivity of this assay was then compared to fecal culture and serologic testing for E. 
coli LPS for diagnosis of STEC infection.  Stx was detected bound to neutrophils in 82% 
of household members screened, versus 10% of household members being positive for 
either fecal culture or serology.  The authors concluded, based on their findings, that 
traditional methods for detection of STEC infection likely underestimate the number of 
infected individuals (150).  Stx binding to human neutrophils in HUS patients was later 
corroborated using a similar flow cytometry technique (146).  This same group also 
found a positive correlation between fecal Stx and neutrophil-bound Stx in the systemic 
circulation of HUS patients (16).   More recently, Griener et. al. compared binding of 
Stx2 to human versus mouse neutrophils.  They found that while Stx2 bound to murine 
neutrophils via the classical Stx receptor Gb3, binding of Stx2 to human neutrophils was 
independent of Gb3 (51).    
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 In contrast, several studies have refuted the finding that Stx binds to 
human neutrophils.  Flagler et. al. examined the effects of Stx1 and Stx2 on neutrophil 
apoptosis and binding.  Neutrophil apoptosis was not affected by Stx, nor was significant 
binding of either toxin to neutrophils observed.  The authors concluded that Stx had no 
direct effect on human neutrophils (40).  Finally, in 2007, the same group that published 
the original series of papers describing Stx binding to PMN refuted their original findings 
in a new study.  They re-examined the specificity of their anti-Stx2 antibody used to 
detect neutrophil-bound Stx, using neutrophils from healthy individuals, hemodialysis 
patients, and peritoneal dialysis patients as controls.  The antibody bound non-
specifically to neutrophils from hemodialysis patients, and the authors concluded that the 
antibody likewise bound non-specifically in HUS patients.  They were unable to detect 
any significant binding of Stx1 to human neutrophils in vitro.  The authors concluded that 
neutrophils were not serving as the mechanism for dissemination of Stx in vivo (47). 
 
Role of platelets in the pathogenesis of HUS 
 
 Since HUS is a thrombotic disorder, with microthrombi formation in multiple 
organs, platelets play an integral part in the pathogenesis.  Peripheral thrombocytopenia 
develops secondary to thrombi formation, and is one of the three key clinical criteria for 
HUS.  Widespread endothelial cell injury leads to exposure of subendothelial collagen 
and platelet activation.  Additionally, several studies have identified a more direct 
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interaction between Shiga-like toxin (Stx) and platelets.   Supernatants from STEC 
culture were shown to activate platelets in vitro (175).  Platelets also express surface Gb3, 
the preferred receptor of Stx1 and Stx2.  An early study identified Stx (derived from 
Shigella dysenteriae only) binding to human platelets via both flow cytometry and thin 
layer chromatography.  Binding was mediated through both Gb3 and a newly described 
glycosphingolipid, identified as band 0.03 (26). Another study noted that Stx1 and its 
isolated binding subunit, Stx1B, bound to platelets, were internalized, and induced 
aggregation.  Stx1 also enhanced fibrinogen binding to platelets, platelet retention, and 
induced platelet binding to cultured umbilical vein endothelial cells in vitro (69).   
The activation status of platelets apparently influences their ability to bind Stx 
directly.  Ghosh et. al. demonstrated that platelets activated via high speed centrifugation, 
EDTA or thrombin exposure had higher concentrations of Gb3 on their surface and 
therefore bound greater amounts of Stx than resting platelets.  Platelet activation status 
was assessed via P-selectin exposure (48).  Moreover, virulence factors of STEC have the 
ability to directly activate platelets.  Both human monocytes and the human monocytic 
cell line THP-1 were shown to produce chemokines such as IL-8 and RANTES following 
exposure to Stx or LPS.  The supernatants from cultured monocytes exposed to Stx 
and/or LPS were then added to isolated human platelets, and activation status was 
assessed via aggregation studies, P-selectin exposure, and serotonin release (54).   
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Role of inflammation and proinflammatory cytokines in the hemolytic uremic 
syndrome. 
 
Although the production and dissemination of Stx is essential for HUS 
development, there is compelling evidence that the interaction of Stx with endothelium 
alone is not sufficient to induce HUS.  A growing body of research exists to implicate 
proinflammatory cytokines as contributing factors in the pathogenesis of HUS.  Several 
studies have discovered an increase in the concentration of proinflammatory cytokines in 
patients who develop HUS over those with STEC-induced diarrhea alone (60, 82, 170).  
Decreased levels of the anti-inflammatory cytokine IL-10 have also been associated with 
HUS development (170, 171).  In several in vitro studies, TNF-α and IL-1β greatly 
enhance the cytotoxicity of Stx.  The direct cytotoxicity of Stx on cultured human 
vascular endothelial cells is minimal; however, when endothelial cells are exposed to 
TNF-α and IL-1β, they are profoundly sensitized to the cytotoxic effects of Stx.  This 
enhancement of Stx cytotoxicity is presumably mediated by the up-regulation of Gb3 on 
endothelial cells (37, 83, 84, 126, 153, 162-164).  One study in particular looked at the 
potential in vitro cytokine production in patients who had experienced an episode of HUS 
using a whole blood stimulation model.  Their findings indicate that HUS patients have a 
propensity to produce greater amounts of several proinflammatory cytokines including 
IL-1, and reduced amounts of the anti-inflammatory cytokine IL-10 (171).   Further 
support for the role of cytokines and inflammation in HUS development is that certain 
indicators of systemic inflammation have been identified as risk factors for HUS 
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development in patients with bloody diarrhea, including leukocytosis and neutrophilia 
(18).    
Increases in proinflammatory cytokine production, particularly TNF-α and IL-1β, 
following exposure to Stx occurs in human monocytes, murine macrophages, and human 
cerebral microvascular endothelial cells (38, 57, 153).  The precise signaling pathway 
involved in Stx induction of proinflammatory cytokines has not been fully characterized. 
The increase in cytokine production by monocytes appears to involve transcriptional 
activation via NF-κB and activator protein-1.  Recent work has shown that functional 
tyrosine kinase activity also is required for TNF-α activation by Stx1 (41, 130). More 
specifically, transcription factors (e.g. c-Jun, NF-κB) and p38 MAPK have been linked in 
the STEC induced signally cascade (19, 42, 130, 149).  Stx 1 and 2 can increase p38 
MAPK activity leading to enhanced TNF-α expression in peripheral blood monocytes 
(19).  NF-κB and c-Jun are also activated by STEC infection and these pathways can lead 
to proinflammatory cytokine expression of TNF-α and IL-1 (42, 130, 149).  Stx exposure 
also increases the stability of cytokine transcripts in human monocytes (57).  TNF-α has 
been shown to enhance clinical disease and depletion of hepatic and splenic macrophages 
(a primary source of systemic cytokine production) decreases lethality in mouse models 
of STEC infection (61, 115).   Based on these studies, hepatic and splenic macrophages 
are implicated as the source of systemic proinflammatory cytokine production in STEC 
infection in vivo.  Chemokine expression is also induced in both macrophages and 
intestinal epithelial cells following exposure to Stx1 and LPS, thereby promoting further 
inflammation via leukocyte recruitment and activation (56, 154).  Although these studies 
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suggest Stx can contribute to proinflammatory cytokine production and inflammation, it 
is not known to what extent this systemic increase in cytokines in vivo is due to 
circulating Stx versus other STEC virulence factors such as LPS.  
 
 
Experimental therapeutics in Hemolytic Uremic Syndrome 
 
Shiga-like toxin Receptor Mimics  
 
 One potential therapeutic approach in STEC infection is to mitigate the effects of 
Stx via the use of Gb3 receptor mimetics, exogenous ligands which interact specifically 
with Stx thereby preventing its interaction with Gb3
 Two main classes of orally administered Stx binding agents have been developed 
to prevent Stx absorption into the peripheral bloodstream.  These are probiotics that 
express a receptor mimic of Gb
 on host cells.  Since the onset of 
systemic disease is preceded in most cases by a prodromal diarrheal phase that lasts 
several days, the opportunity exists to intervene to prevent systemic disease.   There are 
two major classes of receptor mimics that have been produced thus far: oral binding 
agents designed to trap Stx at the site of formation within the gut, and parenterally 
administered compounds that neutralize Stx after it has left the intestinal tract (13, 118).    
3 on their surface and entirely synthetic oligosaccharide 
moieties.  Due to the inherent low affinity between the protein binding subunit of Stx and 
 27 
its carbohydrate receptor, the interaction of the five binding subunits with its ligand is 
complex, and requires engagement of multiple B subunits.  Therefore, in order to be 
effective, these receptor analogues require complex three dimensional structures capable 
of binding multiple binding subunits of the toxin in order to be effective (30, 74-76, 99, 
107, 122).  One of the earliest oral binding agents to be developed, SYNSORB Pk, 
consisted of the oligosaccharide portion of Gb3
More advanced carbohydrate inhibitors of Stx have since been developed that are 
able to engage more of the 15 binding sites per Stx molecule.  STARFISH is a 
pentameric structure of P
 covalently bound to a particle of 
insoluble silicon dioxide (2).  SYNSORB Pk was efficacious at binding and neutralizing 
Stx in vitro, and had no negative side effects in Phase I clinical trials (74, 102).  Its ability 
to neutralize toxin in vitro, however, did not translate to success at preventing serious 
disease in vivo.  The results of a clinical trial in which children with diarrhea-associated 
HUS were treated with either SYNSORB Pk or placebo yielded no significant difference 
between treatment groups in the incidence of either death or significant involvement of 
additional organ systems (156).   The authors proposed several potential explanations for 
the failure of the oral binding agent in this study: 1) oral therapy was initiated too late in 
the course of the disease (e.g. following the clinical diagnosis of HUS) 2) reduced 
gastrointestinal motility in patients limited interaction of the binding agent with 
intraluminal toxin in the colon 3) intimate association of STEC with the GI mucosa 
impaired the ability of the binding agent to adsorb toxin prior to systemic absorption.   
k trisaccharide dimers attached to a core consisting of a single 
glucose molecule.  This multivalent inhibitor is able to engage the five B subunits of Stx 
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in much the same way as its natural ligand, Gb3.  As a result, STARFISH demonstrated 
profound inhibitory activity against Stx1 and Stx2, far surpassing the activity of its 
predecessors (74).  Similarly, another group developed a multivalent analogue of the Gb3 
ligand attached to an acrylamide polymer denoted “SUPER TWIG” (33).  This 
compound was highly efficacious at neutralizing Stx1 and Stx2 in vitro.  Additionally, in 
a mouse model of fatal STEC infection, SUPER TWIG prevented death when 
administered intravenously during the early stages of infection (109).  Oral administration 
of the analogue was similarly effective at preventing brain lesions and death in the same 
mouse model of STEC infection.  SUPER TWIG was efficacious at reducing Stx levels 
in circulation and reducing histologic lesions in the brain (167).   
More recently, a probiotic that expresses Stx receptor mimics on its surface was 
developed for treatment of STEC infection (118).  The probiotic is a recombinant E. coli 
RI strain (CWG308) that contains a plasmid (pJCP-Gb3) encoding several Neisseria sp. 
genes for oligosaccharides that when expressed, create a cell surface mimic of the Stx 
receptor.  The binding capacity of this recombinant strain for either Stx1 or Stx2 is 
approximately 10,000x greater than that of SYNSORB Pk, and this efficacy has been 
corroborated by several in vivo protection studies in mice (117, 118, 123).  This particular 
construct was effective at neutralizing most of the Stx2 variants, Stx2c and Stx2d; 
however, it was less efficacious against Stx2e, which binds preferentially to Gb4.  As a 
result, a new recombinant strain that expressed surface Gb4
 
 was created as a potential 
probiotic strain for use in the prevention of edema disease of swine (117). 
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 One of the main barriers to success for orally administered Stx adsorptive 
compounds is that they have no ability to neutralize toxin once it is absorbed 
systemically.  This is a complicating factor for several reasons.  Firstly, due to the 
reported delay that exists between the start of STEC infection and diagnosis, many 
patients may have already had some systemic Shiga toxemia.  Secondly, despite the 
success of oral binding agents at preventing serious systemic disease in certain animal 
models, this may not correlate to success in a clinical setting.  Based in part on the 
findings of the SYNSORB Pk study, it is plausible that some systemic absorption of toxin 
will occur, even in the presence of an oral Stx binding agent (156).  Therefore, 
parenterally administered compounds may prove more effective at preventing HUS, 
whether used alone or in conjunction with an oral binding agent.  Additionally, because 
of their ability to neutralize toxin within the bloodstream and potentially within the 
organs developing lesions (e.g. brain, kidney, colon), parenterally administered 
compounds may be useful in treatment of HUS.   
One of the most traditional options for a parenterally administered Stx 
neutralizing compound is specific antibody.  Numerous studies in several animal models 
of STEC infection have shown protection from serious negative outcomes using 
parenterally administerd specific antibody to Shiga toxin (passive immunization)(34, 90, 
101, 132, 135, 136).  Active immunization is also successful at preventing systemic 
vascular disease in numerous animal models (14, 50, 177).  The practicality of using 
active immunization is low, considering the relative low risk of HUS development in the 
general population.  Passive immunization as therapy in STEC infection may show 
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promise, and phase one clinical trials have already been completed for a humanized 
monoclonal anti-Stx2 antibody (36). Due to the lack of cross reactivity between antibody 
to Stx1 and Stx2, specific antibody for each toxin must be used if strain phenotyping is 
not performed in each clinical case.   
 
Edema disease of swine 
 
 Edema disease (ED) is a naturally occurring disease of weaned swine caused by 
host-adapted strains of E. coli that produce a variant of Stx2, the edema disease toxin 
(Stx2e).  Edema disease is the only other naturally occurring STEC infection other than 
HUS caused by vascular damage in multiple organs induced by Shiga toxemia.  
Susceptibility to edema disease is age-dependent owing to developmentally regulated 
expression of the intestinal bacterial receptors necessary for colonization.  Colonization 
porcine intestine by edema disease strains is mediated by F18 fimbriae, which bind to 
glycoconjugates on the surface of enterocytes in the distal small intestine whose 
expression is induced at weaning (59).  The most common serogroups of isolates from 
clinical outbreaks are O138, O139, and O141.  Edema disease causes sporadic losses for 
swine herds with variable morbidity and mortality.  Interventions for control of naturally 
occurring disease include antimicrobials, feed changes, and vaccination.   Experimental 
reproduction of ED can be induced either by intravenous administration of Stx2e or by 
oral inoculation with STEC (28).  In an experimental setting, the incidence of clinical ED 
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can be reduced by a variety of measures, including the use of vaccination, antimicrobials, 
probiotics, and administration of specific Stx2e antibody (14, 90, 157).   
  
Virulence attributes of edema disease strains 
 
Stx2e 
 Stx2e is the toxin principal of edema disease, causing vascular necrosis in the 
ileum, brainstem, and subcutis thereby resulting in the characteristic clinical signs.  Stx2e 
was initially described as the edema disease principal, an E. coli verocytoxin produced by 
strains associated with edema disease of swine (81).  The similarity between the edema 
disease principal and Stx2 was subsequently revealed when it was discovered that it was 
neutralized by Stx2, but not Stx1, specific antibody.  Stx2e is approximately 89% and 
50% homologous to Stx2 and Stx1, respectively, based on amino acid sequencing (168).   
Despite the structural similarity between Stx2 and Stx2e, differences in the cytotoxicity 
for cultured cell lines exist between these two toxins.  While both are toxic to Vero cells, 
Stx2e shows reduced toxicity for HeLa cells compared to Stx2.  The reason for this 
disparity is related to differences in ligand preference between the two toxins.  The 
glycolipid receptor preference of Stx2e was identified by thin layer chromatography as 
globotetraosylceramide (Gb4), in contrast toStx2 which binds Gb3.  Vero cells express 
both Gb4 and Gb3, while HeLa cells only express Gb3.   Stx2e also binds to Gb3 and Gb5  
to a lesser extent (32, 71, 131).    
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Edema disease was experimentally reproduced initially by intravenous 
administration of partially purified Stx2e, and later purified Stx2e, to piglets (86, 88).  
Clinical signs of edema disease were induced using as little as 3ng/kg Stx2e 
intravenously, and parenterally-administered purified toxin was also lethal for mice (86).  
Later studies used site-directed mutagenesis to identify which amino acids in the B 
subunit of Stx2e were responsible for the preference of Gb4 over Gb3.  Substitution of the 
Gln64 and Lys66 of Stx2e to the Glu and Gln of Stx2 altered its glycolipid binding 
preference to mimic that of Stx2, binding only Gb3 (159).   This mutant, termed GT3, 
exhibited differing biological behavior in vivo than wildtype Stx2e.  In a pig model, the 
tissue distribution of radiolabeled GT3 was compared to that of wildtype Stx2e and Stx1 
following intravenous administration.  The GT3 mutant behaved in a manner similar to 
Stx1, and showed increased localization to neural tissues (cerebrum, brainstem, and 
cerebellum) and less affinity for the gastrointestinal tract than wildtype.  Wildtype Stx2e 
was found to bind extensively to erythrocytes, which express high levels of its preferred 
ligand, Gb4.  Because of the interaction of Stx2e and erythrocytes, the distribution of 
Stx2e in vivo was affected by tissue blood flow, unlike Stx1 or the GT3 mutant, which 
did not bind significantly to erythrocytes (15).  
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F18 fimbriae 
 
 F18 fimbriae are filamentous bacterial surface antigens composed of 15kDa units 
that mediate colonization of ED STEC in the lower small intestine of swine by binding to 
host enterocyte receptors (59).  Two antigenic variants of F18 are recognized, F18ab and 
F18ac, and are most commonly identified in STEC associated with ED and ETEC 
associated with post-weaning diarrhea, respectively.  F18ab and F18ac fimbriae were 
formally known as F107 and 2134P, respectively (22, 129).  F18 fimbriae recognize the 
F18 receptor (F18R) on the surface of enterocytes, expression of which is 
developmentally regulated and corresponds to weaning; therefore, ED and post-weaning 
diarrhea are age-related disease entities.  Genetic resistance to ED occurs and is mediated 
through activity of the FUT1 gene, which encodes alpha (1,2)-fucosyltransferase (FUT1) 
and thereby indirectly affects expression of F18R (6, 96, 97).  Genetically resistant pigs 
possess a single DNA polymorphism on both alleles resulting in an amino acid switch 
rendering them F18R- (97).  Similar to F18R expression, certain histo-blood group 
antigens (HBGAs), exhibit age-related changes in expression rates and are expressed by 
certain endothelial and epithelial cells in addition to erythrocytes.  Recently, both H-2 
HBGAs and A-2 HBGAs have been implicated in F18-mediated adherence of E. coli in 
porcine intestine (24, 25).   
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Enterotoxins 
 
 Three plasmid-encoded enterotoxins, heat-labile toxin (LT), heat-stabile 
enterotoxin A (STa) and heat-stabile enterotoxin B (STb), are associated with pathogenic 
E. coli  in pigs, and STEC strains causing ED are frequently positive for one or more 
these enterotoxins.  Expression of and response to these toxins in vivo causes the 
prodromal diarrhea associated with many ED outbreaks.  STa and STb are low molecular 
weight polypeptides induce ion secretion into the intestinal lumen.  STa activates 
guanylate cyclase within the cell resulting in increased cGMP levels and subsequent 
chloride and water secretion, while STb induces bicarbonate secretion (59).  LT, like 
Stx2e, is a complex AB5
 Hemolysin is an RTX pore-forming toxin, expression of which results in β-
hemolysis on blood agar plates.  Many STEC and ETEC strains that cause disease in 
 toxin.  LT has a similar mechanism of action to cholera toxin of 
Vibrio cholerae.  Once internalized within the enterocyte, the active A subunit activates 
adenylate cyclase to raise cAMP levels leading to chloride and water secretion from the 
cell (59).  Stx2e itself is mildly enterotoxigenic under certain experimental conditions; 
however, it does not appear to cause fluid secretion within the intestinal tract of pigs and 
therefore is unlikely to directly contribute to diarrhea in ED (87).   
 
Hemolysin 
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piglets are hemolysin-positive, although it is not considered a putative virulence gene in 
these strains.  Hemolysin is plasmid encoded (hlyA), and an isogenic deletion mutant of 
an ETEC strain in gnotobiotic piglets did not affect strain pathogenicity in experimental 
inoculation studies(100).   
 
Clinical edema disease 
 
 ED causes sporadic outbreaks and typically occurs in the 1-2 week period 
following weaning.  Susceptibility is multifactorial, with genetic resistance, declining 
secretory IgA levels from the sow, and diet changes all purported as important factors in 
disease development.  ED outbreaks typically show low morbidity with higher mortality 
(range 15-90%), and traditionally affect the stronger animals in the litter (59).  Outbreaks 
in litters last three days or less, and although recurrence within the same litter is not 
typically observed, recurrence on the same farm is common.   
 Following oral exposure, preferential colonization of ED STEC occurs within the 
lower small intestine (distal jejunum and ileum) (5).  Bacterial adherence is mediated by 
F18 fimbriae, is morphologically evident by 2 days post-inoculation, and occurs mainly 
at the villous tips of enterocytes.  Significant morphologic changes to enterocytes are not 
reported to occur (98).  ED strains that elaborate one or more enterotoxins may cause 
diarrhea prior to clinical ED.   
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Local production of Stx2e within the intestinal lumen occurs as early as 1 day 
post-inoculation (29).  Despite the lack of visible changes in enterocytes following STEC 
colonization, systemic Stx2e absorption occurs soon after colonization, and vascular 
lesions characteristic of Stx2e are evident by two days post-inoculation (98).  The route 
of intestinal absorption of Stx2e remains elusive.  Both Gb3 and Gb4 
Following intestinal absorption, Stx2e is presumed to travel in the systemic 
circulation bound to the surface of erythrocytes.   In an experimental setting, significant 
amounts of erythrocyte-bound Stx2e were detected two hours following intravenous 
Stx2e injection.   The erythrocyte receptor for Stx2e is presumed to be Gb
are expressed in 
porcine jejunum and ileum, although the precise role of these glycolipids in Stx2e 
absorption has yet to be characterized (166).   Under experimental conditions, Stx2e fecal 
titers peak at 4-6 days post-inoculation.  Although fecal Stx2e is a risk factor for clinical 
disease development, fecal Stx2e titers alone are not predictive of clinical outcome for 
individual pigs (29).   Oral administration of Stx2e in pigs does not result in clinical ED; 
however, if intestinal absorption of toxin is experimentally increased with sodium 
deoxycholate, signs of ED are reproduced.  Sodium deoxycholate is an unconjugated bile 
salt that causes increased permeability of the intestinal mucosa to macromolecules (165).   
These findings suggest that increased intestinal permeability may be a factor in Stx2e 
absorption and subsequent disease development.    
4, the preferred 
ligand for Stx2e, since erythrocyte membranes express significant amounts of Gb4 (15).  
Erythrocyte-bound Stx2e is readily transferred to sensitive Vero cells in vitro, thereby 
inducing cell death (29, 91).  Additionally, Stx2e could be detected in the peripheral 
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blood of STEC challenged swine and the presence of erythrocyte-bound Stx2e was 
strongly associated with an increased risk of clinical edema disease.  Stx2e was not 
detected in plasma.  In this study, two different Stx2e erythrocyte-binding types were 
described.  The majority of pigs consistently bound high levels of Stx2e (termed the 
“high-binding phenotype”), while a small number of pigs had erythrocytes that 
consistently bound lower levels of Stx2e (“low-binding phenotype”).   It was proposed 
that the binding phenotype could affect the risk for edema disease development by 
affecting the amount of Stx2e delivered to critical organs (91).  Presumably, variations in 
membrane expression of Gb4
The clinical manifestations of ED are caused by systemic effects of Stx2e.  A 
spectrum of clinical signs is reported.  Milder signs are characterized by subcutaneous 
edema which is typically most pronounced on the eyelids, but may also be noted in the 
submandibular, thoracic, and abdominal areas (59).  The more severe clinical 
manifestations of ED are caused by vascular changes within the brain.  Neurological 
signs in ED include incoordination, changes in gait, ataxia, tremors, paralysis, altered 
squeal, and paddling movements of the limbs (88, 158).  Lateral recumbency and sudden 
death are the most severe manifestations of ED.  Stx2e localization within tissues is 
dependent upon both receptor expression and blood flow (15).   The key target organs 
affected in ED are the brain and intestinal tract.  Gross lesions of ED are typically mild 
and may be absent in some clinical animals (92).  When present, they consist of edema of 
the stomach submucosa, mesentery, mesenteric lymph nodes, and cerebellum.  Serous 
 would account for the differences in Stx2e binding between 
the two phenotypes; however, this has not been experimentally verified.   
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effusion of the abdominal and/or pleural cavities also has been reported (5).  Once the 
toxin is internalized, it disrupts protein synthesis within the cell.  Although apoptosis 
secondary to Stx can be induced experimentally in several cell types, ultrastructural 
examination of vascular lesions from pigs with ED determined that necrosis of 
endothelial cells and myocytes within the tunica media was the predominant change in 
vivo (92).  Despite a range of described microscopic vascular lesions that occur in ED, 
the classical lesion is vascular necrosis of arterioles, commonly of the brain (brainstem, 
meninges, cerebrum) and intestinal tract (submucosa of stomach, intestine, and 
mesentery).  Rarely, vascular lesions can be identified in other organs including pancreas, 
liver, and kidney (70).  Acutely affected pigs may have minimal microscopic lesions, 
consisting of mild perivascular edema and/or karryorhectic debris within myocytes.  
Some acutely affected pigs have more severe vascular lesions, consisting of 
microvascular thrombosis and/or fibrinoid necrosis (98).  Subclinical pigs also have 
vascular lesions, and they are often more pronounced than those of pigs that die acutely.  
Proliferative arteriolar changes are more common in chronic subclinical cases as well.   A 
recent study by Tsukahara et. al. suggests that additional microscopic lesions of ED may 
include eosinophilic enteritis and renal thrombosis; however, the specificity of these 
lesions for STEC infection is questionable (157).   
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Edema disease of swine as a model for STEC infection in human beings. 
 
The edema disease animal model has been used to study HUS (29, 88).   In 
approximately 30% of ED-STEC challenged swine, clinical signs (subcutaneous edema, 
neurological signs, sudden death) of edema disease develop 3-10 days post inoculation 
(5, 29).  The edema disease model has several advantages over other models of HUS, the 
most outstanding of which is that it is a naturally occurring disease.  Edema disease and 
HUS are presumed to share similar early events in their pathogeneses, including localized 
production of toxin in the gut, toxin translocation across gut epithelium, and toxin 
dissemination to target organs via the bloodstream (29, 34).  Additionally, as in human 
STEC infections, not all STEC inoculated swine develop systemic disease; the majority 
of pigs undergo an uncomplicated recovery from the diarrhea phase.  Other advantages 
include a similar time course of pathogenic events including a prodromal diarrhea phase 
with delayed development of systemic complications (29).  A comparison of the 
pathogenesis between HUS and edema disease is made in Table 1.   
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Table 1: Comparison of pathogenesis between HUS and edema disease.  Unknowns 
highlighted with italics are to be addressed by the research outlined in this thesis. 
Element of Disease Pathogenesis 
 
Hemolytic Uremic  
Syndrome 
Edema 
Disease 
Anatomic location of bacterial colonization Colon Lower small 
intestine 
Primary virulence factor Stx1 and Stx2 Stx2e 
Primary toxin receptor on target cells (vascular 
endothelium) 
Gb3 Gb4 
Proposed blood carrier responsible for toxin 
dissemination 
Neutrophil (?) Erythrocyte 
Target organs Kidney, brain, colon 
 
Ileum, 
brainstem 
Monocytes and/or macrophages produce pro-
inflammatory cytokines following exposure to 
Shiga toxin  
Stx1 and Stx2:  
Yes 
Stx2e: 
Unknown 
Circulating Shiga toxin detected in individuals that 
develop systemic clinical disease 
Yes Yes 
Circulating Shiga toxin detected in individuals that 
fail to develop systemic clinical disease 
Yes Yes 
Increased proinflammatory cytokines in 
individuals with clinical disease 
Yes Unknown 
Increased cytokines secondary to Shiga toxin 
dissemination in clinical individuals 
Presumed, but unclear Unknown 
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Hemolytic uremic syndrome is a systemic and potentially fatal complication of 
Shiga toxin-producing Escherichia coli (STEC) in human beings, and is a leading cause 
of renal failure in children.  Edema disease, an infection of swine caused by host adapted 
STEC, shares a similar pathogenesis to hemolytic uremic syndrome and is used as an 
animal model to study this disease.  Previously, we have prevented edema disease in 
STEC inoculated pigs with parenteral administration of antibody to Shiga toxin.  This 
study describes the effect of treatment with a probiotic expressing surface globotetraose, 
the preferred oligosaccharide receptor for Shiga toxin 2e (Stx2e), on clinical edema 
disease.  STEC inoculated pigs were treated with the probiotic (5 x 10
3 
 
Abstract 
11 CFU) twice daily 
from days 1-10 post inoculation.  Treatment with the probiotic significantly reduced 
intestinal Stx2e, as reflected by decreased fecal toxin titers on days 1-10 post-inoculation 
 54 
(p<0.05).  Despite this reduction of intestinal toxin, treatment failed to reduce vascular 
necrosis in target organs and had no effect on the incidence of clinical disease in STEC 
inoculated pigs.  These findings suggest that treatment with an oral Stx binding agent 
may not be as efficacious at preventing systemic disease secondary to Shiga toxemia as 
parenterally administered specific antibody in a naturally occurring STEC infection.   
 
Introduction 
A small percentage of patients (5-15%) with diarrhea secondary to Shiga toxin 
producing Escherichia coli (STEC) infection develop a systemic and potentially fatal 
complication known as hemolytic uremic syndrome (HUS), characterized by the triad of 
hemolytic anemia, thrombocytopenia, and acute renal damage.  HUS is more prevalent in 
children under the age of 10 and the elderly, and it remains the leading cause of renal 
failure in children in the United States (Paton and Paton 1998; Siegler and Oakes 2005; 
Tarr, Gordon et al. 2005).  At present, there is no known method to predict which patients 
with diarrhea caused by STEC will develop HUS, and no known treatment for the 
disorder once it is diagnosed.   
One potential therapeutic approach is to neutralize the activity of Shiga toxin 
(Stx), the principle mediator of HUS development in STEC patients.  The preferred 
receptor for Stx1, Stx2, and most of its variants is globotriaosylceramide (Gb3); however, 
globotetraosylceramide (Gb4) is the preferred receptor of Stx2e, the Stx2 variant which is 
primarily associated with edema disease of swine (Boyd, Tyrrell et al. 1993).  Following 
STEC colonization, Stxs are produced locally within the intestine, then cross the 
intestinal mucosa and vascular endothelium to gain access to the bloodstream.  Once the 
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toxin reaches the blood, it binds the receptor on the surface of vascular endothelial cells 
in key target organs (kidney, brain) and is internalized (Jacewicz, Clausen et al. 1986).  
Toxin internalization within endothelial cells results in inhibition of protein synthesis, 
leading to cell death (Paton and Paton 1998). Recent studies in animal models of STEC 
infection have had success in preventing systemic complications associated with Stx 
through the use of specific antibody that binds and neutralizes Stx (Matise, Cornick et al. 
2001; Mukherjee, Chios et al. 2002; Sheoran, Chapman et al. 2003; Sheoran, Chapman-
Bonofiglio et al. 2005).   Several other synthetic compounds have been developed to bind 
and/or neutralize Stx in the gut prior to systemic absorption.  One such compound, 
SYNSORB Pk, was created by attaching synthetic carbohydrate mimics of the Stx 
receptor, Gb3, onto the surface of diatomaceous earth (Takeda, Yoshino et al. 1999).  
Synsorb PK was designed as an oral therapeutic compound that would theoretically trap 
Stx at the site of production within the intestinal lumen, thereby preventing systemic Stx 
absorption.  Despite promising data from in vitro studies looking at toxin neutralization, 
Synsorb Pk failed to reduce the incidence of HUS in clinical trials.   
More recently, a probiotic that expresses Stx receptor mimics on its surface was 
developed for treatment of STEC infection (Paton, Morona et al. 2000).  The probiotic is 
a recombinant E. coli RI strain (CWG308) that contains a plasmid (pJCP-Gb3) encoding 
several Neisseria sp. genes for oligosaccharides that when expressed, create a cell surface 
mimic of the Stx receptor.  The binding capacity of this recombinant strain for either Stx1 
or Stx2 is approximately 10,000x greater than that of Synsorb Pk, and this efficacy has 
been collaborated by several in vivo protection studies in mice (Paton, Morona et al. 
2000; Paton, Morona et al. 2001; Paton, Rogers et al. 2001).  This particular construct 
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was effective at neutralizing most of the Stx2 variants, Stx2c and Stx2d; however, it was 
less efficacious against Stx2e, which binds preferentially to Gb4.  As a result, a new 
recombinant strain that expressed surface Gb4 was created as a potential probiotic strain 
for use in the prevention of edema disease of swine(Paton, Morona et al. 2001). 
  
Edema disease, an infection of weaned swine caused by host-adapted strains of E. 
coli, has been used as an animal model of systemic STEC disease in human beings 
(Cornick, Matise et al. 2000) .  In this model, approximately 30% of STEC challenged 
swine succumb to clinical disease secondary to Shiga toxemia, characterized by 
subcutaneous edema, neurological signs and/or sudden death (MacLeod, Gyles et al. 
1991).  The edema disease model has several advantages over other models of HUS, the 
most outstanding of which is that it is a naturally occurring disease.  Edema disease and 
HUS share similar early events in their pathogeneses, including localized production of 
toxin in the gut, toxin translocation across gut epithelium, and dissemination to target 
organs via the bloodstream (Donohue-Rolfe, Kondova et al. 1999; Cornick, Matise et al. 
2000).  Additionally, as in human STEC infections, not all STEC inoculated swine 
develop systemic disease; the majority of pigs undergo an uncomplicated recovery from 
the diarrhea phase.  Other advantages include a similar time course of pathogenic events 
manifested by a prodromal diarrhea phase with delayed development of systemic 
complications (Cornick, Matise et al. 2000).   
We hypothesized that treatment with the probiotic expressing surface 
globotetraose would bind and trap Stx2e within the intestinal lumen, thereby reducing 
systemic toxin absorption and preventing clinical edema disease.  The purpose of this 
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study was to investigate whether this probiotic would decrease the incidence of clinical 
edema disease in STEC-challenged swine.    
A preliminary report of this work was made at the Annual Meeting of the 
American Society for Microbiology, May 2006, Orlando, FL 
 
 
Materials and Methods 
Bacterial strains.  S1191 is an STEC strain isolated from a pig with edema 
disease.  This strain belongs to serogroup O139, is resistant to chloramphenicol, and 
produces Stx2e, hemolysin, F18ab fimbriae and heat-stable enterotoxin B (L.R.M. 
Marques 1987).  Strain 123 is a non-pathogenic E. coli, serogroup O43, isolated from a 
healthy pig.  Inocula were prepared as described previously (Sarmiento, Casey et al. 
1988; Cornick, Matise et al. 2000). 
 Creation of the probiotic strain, an E. coli R1 derivative expressing surface 
GalNAcβ(1→3)Galα(1→4)Galβ(1→4)Glc (globotetraose), has been described in detail 
previously (Paton, Morona et al. 2001).  Briefly, three Neisseria sp. glycosyltransferase 
genes (lgtC, lgtE, and lgtD) and a UDP-GalNAc-4-epimerase gene (gne) were cloned into 
the plasmid vector pK184 to create plasmid pGb4 and inserted into a derivative of E. coli 
R1 (CWG308).  This strain has a waaO mutation in the outer core lipopolysaccharide 
(LPS) biosynthesis locus that results in production of a truncated LPS core terminating in 
glucose.  Expression of the plasmid-encoded glycosyltransferase genes results in linkage 
of GalNAcβ(1→3)Galα(1→4)Galβ(1→4) onto the terminal glucose.  The sham strain is 
the E. coli derivative R1 (CWG308) with the plasmid vector pK184 only.  The treatment 
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and sham strains were grown overnight in tryptic soy broth plus kanamycin (30 μg/ml) 
and IPTG (20 μg/ml), concentrated 100× and resuspended in TSB containing 10% 
NaCO3, 20% sucrose and 21% glycerol.  Treatments were stored at -80C and thawed just 
prior to use. 
Reproduction of clinical edema disease.  Animal experiments were carried out 
in accordance with the Iowa State University Animal Care and Use Committee.  The 
study design proposed here to reproduce clinical edema disease follows a previously 
described protocol and is outlined in Table 1 (Cornick, Matise et al. 2000). Briefly, two 
week-old crossbred pigs were acclimated to a high soy protein diet for one week prior to 
challenge (Bosworth 2002).  Sixty pigs (twenty pigs per trial, three separate trials) were 
inoculated orally with 1010 CFU of STEC strain S1191 eight days after weaning.  Control 
pigs (ten pigs) received 1010
 
 CFU of the non-pathogenic E. coli strain 123.  Pigs were 
monitored twice daily for clinical signs of edema disease (subcutaneous edema, 
recumbency or neurological disturbances such as ataxia, circling or sudden death).  Pigs 
that developed neurological signs were euthanized by an intravenous overdose with 
barbiturate.  Pigs that failed to develop neurological signs were euthanized at the 
termination of the study (14 days post-inoculation).  All pigs underwent a complete 
necropsy, with inspection of major organs for gross lesions and collection of tissue 
samples from ileum and brainstem in neutral buffered formalin for histology.  
Hematoxylin and eosin stained sections of ileum and brainstem were examined by a 
pathologist blinded to the study for evidence of vascular necrosis (positive if two or more 
necrotic vessels were identified) (Matise, Sirinarumitr et al. 2000).   
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 Treatment with the probiotic.  Pigs inoculated with STEC strain S1191 were 
treated with either E. coli CWG308 containing the plasmid pGb4 (probiotic; thirty pigs in 
total) or CWG308 containing the vector pK184 only (sham; thirty pigs in total).  
Individual pigs were orally dosed with 5 × 1011 CFU of either strain twice daily for 10 
days beginning day 1 post-inoculation.  
 
 Determination of Stx2e in feces.  Feces were collected daily from control and 
STEC-inoculated pigs, on days 1-10 post-inoculation, and stored at 4o
Bacterial colonization.   STEC strain 1191 was recovered from all of the challenged pigs 
(probiotic and sham groups) at both 2 and 5 days post inoculation.  The probiotic E. coli 
strain CWF308 (pJCPGb
C until processing.  
Stx2e concentrations were assessed using a Vero cell assay as described previously 
(Cornick, Matise et al. 2000).  Briefly, samples were diluted two-fold in PBS and added 
to monolayers of Vero cells in microtiter plates.  Toxin titers were expressed as the log of 
the reciprocal of the greatest dilution that resulted in ≥ 50% Vero cell death.  Specificity 
of the titers for Stx2e was confirmed by neutralization with anti-Stx2e antibody. 
 
Statistical analysis.  Incidences of vascular lesions and clinical disease between 
probiotic and sham groups were compared using Fisher’s exact test.  Fecal toxin titers 
were compared between treatment groups using repeated measures ANOVA.   
 
 
 
Results 
4) was recovered from all pigs in the probiotic treated group at 
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both 2 and 5 days post inoculation.   None of the negative control pigs shed STEC at 
either time-point.   
 
Clinical disease.  Seven out of sixty pigs inoculated with the STEC strain 1191 
developed clinical edema disease over three replicates of the trial (Table 2).  During the 
first experimental replicate, two of the pigs in the sham treated group and none of the 
pigs in the probiotic treated group developed clinical disease.  One of the STEC 
inoculated pigs within the sham treated group and one within the probiotic treated group 
developed clinical disease during the second replicate, and one in the sham and two in the 
probiotic developed edema disease during the third replicate. Of the pigs with clinical 
edema disease, three exhibited neurological signs prior to euthanasia and four were found 
dead.  None of the ten pigs inoculated with the non-pathogenic E. coli strain 123 
developed clinical signs of edema disease or died.  In summary, three of the seven 
clinically affected pigs were in the probiotic treatment group, and four were in the sham 
group resulting in an overall disease incidence of 10% in the probiotic group and 13% in 
the sham group.   
      
Vascular lesions.  Brainstem and ileum were assessed for vascular evidence of Shiga 
toxemia microscopically.  Histologic evidence of edema disease (vascular necrosis in two 
or more vessels per tissue) was not detected in any of the ten pigs inoculated with the 
non-pathogenic E. coli strain.     Vascular lesions consistent with edema disease (Figure 
1) were identified in the ilea of 26/60 and in the brainstem of 24/60 STEC inoculated pigs 
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(Table 2).  Although the incidence of vascular lesions was slightly lower in the probiotic 
treated group, the results were not statistically significant (p>0.05, Chi Square test).  
  
Fecal and blood toxin titers.    Stx titers were measured in both feces and blood to 
assess the efficacy of the probiotic at adsorbing Stx within the intestinal lumen.  Increases 
in fecal Stx titers in both of the STEC inoculated groups were detectable beginning day 1 
post inoculation, and peaked on days 5-7 post inoculation (Figure 2A).  Stx2e titers in the 
sham group were significantly higher than the negative control group on all days that 
samples were collected (days 1-10 post inoculation, p<0.05, ANOVA).  Treatment with 
the probiotic reduced the fecal Stx2e levels from 2-20 times compared to the sham treated 
group (p<0.05, Student’s t-test).  None of the control pigs had detectable Stx2e in their 
feces at any time point throughout the study.  Stx2e was not detected in the blood of the 4 
pigs that exhibited neurological signs typical of clinical edema disease prior to euthanasia 
(data not shown).   
 
Comparison of fecal toxin titers between clinical and non-clinical pigs.  Fecal toxin 
titers in clinical pigs were compared with titers in non-clinical pigs in both the sham and 
probiotic treatment groups.  Since all pigs that developed edema disease fell ill prior to 
day 8 post inoculation, fecal titers are not available for these pigs beyond day 7 post 
inoculation.  Although treatment with the probiotic reduced fecal toxin titers overall, 
those pigs treated with the probiotic that developed clinical disease had, on average, toxin 
titers similar to the sham treated group and were significantly different than probiotic 
treated subclinical pigs on days 3-5 post inoculation (Figure 2B).   
 62 
 
Discussion 
 
 
The probiotic strain expressing globotetraose used in this study was designed 
specifically to bind and neutralize Stx2e, the toxic principal of piglet edema disease.  This 
construct was effective at neutralizing 98.4% of Stx2e cytotoxicity in vitro (Paton, 
Morona et al. 2001). The dose of probiotic and frequency of administration used here 
were extrapolated from previous studies with a similar probiotic expressing a surface Gb3
In mice, treatment with a probiotic expressing a Gb
 
mimic in a mouse model of STEC infection. In STEC inoculated piglets, treatment twice 
daily with the probiotic was very effective at reducing the intestinal concentration of 
Stx2e, as reflected in the reduced fecal toxin titers in the probiotic group.  However, 
treatment with the probiotic failed to reduce the incidence of vascular lesions and clinical 
disease in STEC inoculated swine, indicating systemic absorption of Shiga toxin still 
occurred.   Interestingly, those pigs that developed clinical disease within the probiotic 
group had significantly higher fecal toxin titers than subclinical pigs within this group, 
with the average toxin titers of clinical pigs approaching those of the sham treated groups 
prior to clinical disease onset.  This could indicate a failure of the probiotic to reduce 
toxin titers in those pigs that broke with clinical disease, despite an overall reduction in 
toxin titers within this treatment group.   
3 mimic was protective against 
fatal systemic complications of infection with human-derived STEC  (Paton, Morona et 
al. 2000).  There are several differences between the mouse studies and the current study 
that may have influenced treatment outcome. The affinity of the Gb4 mimic bacterium for 
Stx2e is not quite as high as that of the previously described Gb3 mimic for other 
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members of the Stx family that was used in the mouse studies (Paton, Morona et al. 
2001). This reduced affinity may have resulted in sub-optimal retention of Stx2e in the 
gut lumen. Another disparity between these studies is the timing of probiotic treatment.  
In mice, treatment with the probiotic strain was initiated at the time of STEC challenge.  
Our experimental design delayed treatment for 24 hours in an attempt to more closely 
mimic post-exposure therapy.  As a result, pigs in this study were exposed to intestinal 
Stx2e prior to treatment with the probiotic.  Pigs are known to be extremely susceptible to 
intravenous Shiga toxin (LD50 3 ng/kg) (MacLeod, Gyles et al. 1991).  It is likely that the 
early and continuous exposure to systemic toxin absorbed from the gut initiates an 
irreversible cascade of events leading to clinical disease development in some pigs.  This 
may represent an obstacle for post-exposure therapy in human beings because of the 
delay between the onset of diarrhea and diagnosis in STEC infections (Tarr, Gordon et al. 
2005).  Similarly, when probiotic treatment was delayed in the mouse model for 24 or 48 
hrs, mice were not protected from death when challenged with the most virulent STEC 
strain (Paton, Rogers et al. 2001).  Finally, the lack of normal gastrointestinal flora in the 
streptomycin-treated mouse model could potentially facilitate physical interaction 
between the STEC and probiotic strains, thereby enhancing its efficacy. The commensal 
flora of the ileum in pigs could impede the distribution and/or interaction of the probiotic 
strain.  Based on the outcome of this study, probiotic therapy may be less effective at 
preventing systemic complications in a naturally occurring STEC infection than 
parenteral antibody administration.  Previously we have shown that a single dose of 
parentally delivered anti-Stx2e antibody given up to 4 days post-inoculation protects pigs 
against clinical edema disease(Matise, Cornick et al. 2001).  Similarly, Sheoran et al. 
 64 
reported that human anti-Stx2 administered 48 hours after the onset of diarrhea protected 
gnotobiotic piglets from fatal complications of Shiga toxemia (Sheoran, Chapman-
Bonofiglio et al. 2005).   
The unexpected results obtained here are similar to those from previous studies 
that employed a different oral Stx binding agent, SYNSORB Pk, which did not protect 
children with HUS from developing extrarenal complications or death, despite the 
compounds’ ability to bind and neutralize Stx in vitro (Takeda, Yoshino et al. 1999; 
Trachtman, Cnaan et al. 2003).  Several potential explanations for SYNSORB Pk’s lack 
of efficacy in clinical trials were proposed: 1)  therapy was initiated too late in the disease 
process after systemic absorption of Stx had already occurred; 2) altered gastrointestinal 
motility seen in STEC patients affected delivery to the colon, thereby diminishing the 
drugs effectiveness; 3) the intimate association of STEC with the intestinal mucosa may 
have limited the ability of the compound to interact with Stx within the intestinal lumen 
(Trachtman, Cnaan et al. 2003).  Although no studies have been published to specifically 
document altered gastrointestinal motility in pigs with edema disease, pigs often have a 
prodromal diarrhea phase, and GI motility is likely altered in edema disease as well.  This 
may have affected transit time of the probiotic, and could have affected its ability to bind 
Stx2e within the intestinal lumen, thereby diminishing its effectiveness.  Finally, although 
attaching and effacing lesions are not formed by the STEC strains responsible for edema 
disease, the bacteria form intimate attachments to the intestinal mucosa.  This intimate 
association between pathogen and mucosa may allow Stx2e to reach and cross the 
mucosa before the toxin has a chance to interact with the probiotic within the intestinal 
lumen.     
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In conclusion, the results of this study in the edema disease model show that 
treatment with a Stx2e-receptor mimic probiotic significantly reduced fecal Stx2e titers; 
however, the probiotic failed to prevent vascular necrosis in target organs and provided 
no protection against clinical disease.Our findings suggest that treatment with an oral Stx 
binding agent is less effective than specific antibody at preventing systemic 
complications during naturally occurring STEC infection.   
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Figures and Tables 
 
Figure 1.  Histological confirmation of vascular injury secondary to Shiga toxemia in ilea 
(submucosa).  Arterioles in control pigs inoculated with non-pathogenic Escherichia coli 
lacked lesions (A).  Arteriole from pig inoculated with Shiga toxin producing E. coli 
(STEC) strain S1191 and treated with the sham strain (B).  Segmental changes within the 
tunica media characterized by the presence of karyorrhectic nuclear debris from a 
myocyte (arrow).  Arteriole from pig inoculated with STEC strain S1191 and treated with 
the receptor mimic probiotic (C).  Note nuclear remnants of myocytes within the tunica 
media (arrows), as well as vacuolization of the sarcoplasm (arrowhead).  These findings 
indicate that treatment with the receptor mimic probiotic failed to prevent Shiga toxemia.   
Hematoxylin and eosin, ×1000 magnification.    
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Figure 1 (continued) 
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Figure 2.  Effect of treatment with a probiotic expressing globotetraose on mean fecal 
Shiga toxin 2e titers in Shiga toxin-producing Escherichia coli inoculated pigs. A. 
Treatment with the probiotic significantly reduced titers compared to sham treated pigs 
on all days post inoculation (*, p<0.05, repeated measures ANOVA).  B. Although fecal 
Shiga toxin levels were reduced overall within the probiotic group, pigs that developed 
clinical edema disease had higher levels of fecal Shiga toxin, similar to those of the sham 
treated group (*, p<0.05).   
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Figure 2 (continued) 
 
B. 
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Table 1.  Experimental design to assess the effect of a probiotic expressing Gb4 
Experimental 
group 
on the 
incidence of edema disease. 
 
Number 
of pigs
Pig age at 
inoculation a 
Inoculation 
strain 
Treatment 
Probiotic 30 24-26 days S1191 CWF308(pJCPGbc 4) 
Sham 30 24-26 days S1191 CWF308 c 
Negative 
control  
10 24-26 days 123 None b 
a Each group represents the cumulative number of pigs from three separate experimental replications 
b Non-pathogenic E. coli strain  
c STEC strain  
 
 
 
 
Table 2.  Incidences of clinical disease and vascular lesions in pigs inoculated with 
STEC 1191 and treated with a Gb4 expressing probiotic vs. a sham strain lacking Gb4. 
No significant differences between groups were identified (p>0.05, Chi square test).   
 
 
 
 
Experimental 
group 
Number 
of pigs
Incidence of 
clinical 
disease 
d 
Incidence of 
vascular lesions in 
brainstem 
Incidence of 
vascular lesions in 
ileum 
Probiotic 30 a 3/30 10/30 11/30 
Sham 30 b 4/30 14/30 15/30 
Negative 
control
10 
c 
0/10 0/10 0/10 
a Inoculated with STEC strain, treated with probiotic 
b Inoculated with STEC strain, treated with sham 
c Inoculated with non-pathogenic E. coli strain, no treatment 
d Sum of three experimental replicates 
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Chapter 3: Proinflammatory cytokine responses in naturally occurring Shiga-toxin 
producing Escherichia coli infection in piglets. 
 
A manuscript to be submitted to Veterinary Immunology and Immunopathology 
 
S.J. Hostetter1, J.M. Gallup1, and N.A. Cornick2
Hemolytic uremic syndrome (HUS), a systemic and potentially fatal complication 
of Shiga toxin-producing Escherichia coli (STEC) infection, is a leading cause of renal 
failure in children.  The goal of this study was to characterize the proinflammatory 
cytokine changes during STEC infection in experimental porcine edema disease, an 
animal model of HUS.  Piglets were inoculated with either a Stx2e-producing host 
adapted (STEC group) or non-pathogenic (control) E. coli strain.   Clinical edema disease 
was observed between days 5 and 10 post-inoculation with a clinical disease incidence of 
35% in the STEC group.  Clinical pigs had significantly higher fecal Stx concentrations 
than subclinical pigs on days 2 and 5 post-inoculation.   At day 2 post inoculation, plasma 
TNF-α was significantly higher in STEC inoculated pigs that went on to develop clinical 
disease.  Liver TNF-α and IL-1β protein levels were significantly higher in clinical STEC 
pigs compared to either subclinical STEC pigs or controls.  Ileal IL-10 levels in 
subclinical STEC pigs were significantly increased compared to both clinical STEC pigs 
and controls, and brainstem IL-10 was higher in subclinical STEC pigs than controls.   In 
. 
1: Iowa State University, Department of Veterinary Pathology 
2: Iowa State University, Department of Veterinary Microbiology and Preventive Medicine 
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an attempt to further clarify the contribution of Stx2e to the enhanced TNF-α levels 
observed in livers of clinical pigs, porcine macrophages were stimulated with either 
Stx2e or erythrocyte-bound Stx2e.  Neither Stx2e nor erythrocyte-bound Stx2e were 
potent stimulators of TNF-α production by porcine macrophages.  In conclusion, higher 
levels of liver IL-1β and TNF-α were detected in clinical pigs than subclinical pigs.  This 
could indicate a greater systemic inflammatory response in STEC inoculated pigs that 
develop clinical disease.  Importantly, clinical pigs had higher levels of plasma TNF-α 
prior to the onset of clinical disease, making plasma TNF-α a potential candidate for 
systemic disease risk assessment in STEC infected individuals. 
 
Introduction 
 
Hemolytic uremic syndrome (HUS), a systemic complication of Shiga toxin-
producing Escherichia coli (STEC) infection, is the number one cause of renal failure in 
children in the United States (Karmali, 1989, 2004; Paton and Paton, 1998).  STEC are a 
common cause of food-borne illness in the United States, and ruminants are the primary 
reservoir.  Individuals are typically exposed through ingestion of either undercooked 
ground beef or raw fruits and vegetables contaminated with STEC or person-person 
transmission (Karmali, 2004) .  Following colonization, Shiga toxins (Stx) are produced 
locally within the intestine, then presumably cross the intestinal mucosa and vascular 
endothelium to gain access to the bloodstream.  It has been shown in tissue culture 
systems that biologically active Stx can cross intestinal epithelial cells, and that 
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neutrophil transmigration across epithelial monolayers enhances Stx translocation 
(Acheson et al., 1996; Hurley et al., 2001).   Once the toxin reaches the blood, it binds 
globotriasoyl ceramide (Gb3
Although the production and dissemination of Stx is essential for HUS 
development, there is compelling evidence that the interaction of Stx with endothelium 
alone is not sufficient to induce HUS.  A growing body of research exists that implicates 
proinflammatory cytokines as contributing factors in the pathogenesis.  Several studies 
have discovered an increase in the concentration of proinflammatory cytokines in patients 
who develop HUS over those with STEC-induced diarrhea alone (Inward et al., 1997; 
Lopez et al., 1995; Westerholt et al., 2000).  Decreased levels of the anti-inflammatory 
cytokine IL-10 have also been associated with HUS development (Westerholt et al., 
2000; Westerholt et al., 2003). One study in particular looked at the potential in vitro 
cytokine production in patients who had experienced an episode of HUS using a whole 
blood stimulation model.  Their findings indicate that HUS patients have a propensity to 
produce greater amounts of several proinflammatory cytokines including IL-1, and 
reduced amounts of the anti-inflammatory cytokine IL-10 (Westerholt et al., 2003).   In 
several in vitro studies, TNF-α and IL-1β greatly enhance the cytotoxicity of Stx.  The 
) on the surface of vascular endothelial cells in key target 
organs (kidney, brain) and is internalized (Jacewicz et al., 1986).  Toxin internalization 
within endothelial cells results in inhibition of protein synthesis, leading to cell death 
(Furutani et al., 1990).   The resultant vascular necrosis can lead to the formation of 
thrombi within affected vessels in susceptible individuals, and subsequently produce the 
characteristic clinical triad of HUS (microangiopathic anemia, thrombocytopenia, and 
acute renal damage (Mark Taylor, 2008).   
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direct cytotoxicity of Stx on cultured human vascular endothelial cells is minimal; 
however, when endothelial cells are exposed to TNF-α and IL-1β, they are profoundly 
sensitized to the cytotoxic effects of Stx.  This enhancement of Stx cytotoxicity is 
presumably mediated by the up-regulation of Gb3 on endothelial cells (Eisenhauer et al., 
2001; Louise and Obrig, 1991; Louise et al., 1997; Ramegowda et al., 1999; Tesh et al., 
1994; Van de Kar et al., 1993; van de Kar et al., 1995; van Setten et al., 1997).   More 
recently, a study in a rabbit model revealed that inflammation secondary to Stx2-induced 
vascular damage within the central nervous tissue exacerbated degenerative changes 
within the tissue (Takahashi et al., 2008).  Further support for the role of cytokines and 
inflammation in HUS development is that certain indicators of systemic inflammation 
have been identified as risk factors for HUS development in patients with bloody 
diarrhea, including leukocytosis and neutrophilia (Buteau et al., 2000).   Finally, 
increases in proinflammatory cytokine production, particularly TNF-α and IL-1β, 
following exposure to Stx occurs in human monocytes, murine macrophages, and human 
cerebral microvascular endothelial cells (Eisenhauer et al., 2004; Harrison et al., 2004; 
Tesh et al., 1994).  Although these studies suggest Stx can contribute to proinflammatory 
cytokine production and inflammation, it is not known to what extent this systemic 
increase in cytokines in vivo is due to circulating cell-bound Stx versus other STEC 
virulence factors, such as LPS. 
The goals of this study were to: a) characterize and compare the proinflammatory 
cytokine response between clinical versus subclinical piglets with systemic STEC 
infection b) assess the potential of Stx itself to promote proinflammatory changes in 
STEC infection and c) identify predictors of systemic disease during the initial stages of 
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STEC infection.  To accomplish these goals, we compared local and systemic Shiga toxin 
levels, as well as TNF-α, IL-1β and IL-10 levels, and compared clinical versus 
subclinical individuals in our animal model of systemic STEC infection, edema disease 
of swine.  We also evaluated the ability of cell-bound Stx to induce cytokine production 
in porcine macrophages in vitro, and compared the effects to cell-bound LPS.  We 
hypothesized that clinical pigs would have a greater proinflammatory response than 
subclinical pigs, and that this response was due to greater Stx production and 
dissemination in these pigs.  Additionally, we proposed that clinical pigs would have 
evidence of a greater proinflammatory response prior to the onset of clinical signs.  We 
chose edema disease of swine as the animal model to test these hypotheses because of the 
similar pathogenesis to HUS.  Edema disease is a naturally occurring STEC disease of 
weanling swine caused by host-adapted strains of E. coli that produce a Stx2 variant, 
Stx2e. Experimentally infected swine are colonized predominantly in the ileum, suffer a 
prodromal diarrhea phase, and approximately 30% of individuals develop clinical edema 
disease manifested by neurological symptoms due to systemic Shiga toxemia (Cornick et 
al., 1999, 2000; MacLeod et al., 1991).  Stx2e,  the primary virulence factor in edema 
disease, is detected in peripheral blood bound to porcine erythrocytes, and the presence of 
erythrocyte-bound Stx2e is strongly associated with the development of clinical disease 
(Matise et al., 2003).   Our findings in this model support a role of a proinflammatory 
cytokine response in clinical disease development in STEC infection, and show that this 
response begins prior to the onset of clinical disease.   
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Materials and Methods 
 
Bacterial strains: Strain S1191, an STEC strain isolated from a pig with clinical 
edema disease, belongs to serogroup O139 and produces Stx2e, hemolysin, F18ab 
fimbriae, and heat-stable enterotoxin B (L.R.M. Marques, 1987; Sarmiento et al., 1988).  
S1191 is hemolytic on sheep blood agar and is resistant to chloramphenicol.  Non-
pathogenic E. coli strain 123 belongs to serogroup O43 and was isolated from a healthy 
pig.  Inocula were prepared as described elsewhere (Sarmiento et al., 1988).       
 
Reproduction of clinical edema disease:  Animal experiments were carried out 
in accordance with a protocol approved by the Iowa State University Animal Care and 
Use Committee.  Two week-old crossbred swine were purchased from a commercial 
facility and housed in a biosafety level II animal facility at Iowa State University. The 
study design to experimentally reproduce edema disease follows a previously described 
protocol (Cornick et al., 2000; Matise et al., 2003).  Briefly, swine (20) were inoculated 
orally with 1010 colony forming units (CFU) of STEC strain S1191 8-10 days after 
weaning.  Control pigs (5) received 1010 CFU orally of non-pathogenic E. coli strain 123.  
Pigs were fed a custom antibiotic-free soy protein diet and monitored twice daily for 
evidence of edema disease (subcutaneous edema, recumbency, or neurological 
disturbances such as ataxia and circling).  For the purposes of this study, piglets were 
considered to manifest clinical systemic disease only when neurologic signs or sudden 
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death were observed, since some piglets with mild signs (e.g. subcutaneous edema) 
recover uneventfully.  Pigs that developed neurological signs (clinical pigs) were 
euthanized by intravenous overdose with barbiturate.  Those pigs that failed to develop 
neurological signs (subclinical pigs) were euthanized in a similar manner at the 
termination of the study (14 days post-inoculation).  Pigs inoculated with the non-
pathogenic E. coli strain were also euthanized at day 14 post-inoculation.  Feces 
(collected daily) and blood (collected every other day in EDTA) were collected from all 
pigs for analysis of Stx levels (feces and packed red blood cells) or cytokine protein 
levels (plasma).  All pigs underwent a complete necropsy, with inspection of major 
organs for gross lesions, and collection of samples from ileum and brainstem (tissues 
known to develop vascular lesions in edema disease), as well as  liver and kidney (tissues 
chosen for evaluation of more systemic responses) for cytokine protein levels and qRT-
PCR.   
 
Toxin and reagents:  Crude Stx2e was prepared from whole cell lysate of E. coli 
strain DH5α containing a plasmid encoding the Stx2e gene as described previously 
(Matise et al., 2003; Samuel et al., 1990).  Stx2e was purified using an affinity column 
containing a carbohydrate analogue of the Stx receptor, Gb3 (Nakajima et al., 2001).  The 
final Stx2e concentration in the purified preparation was approximately 65 μg/ml, Vero 
cell titer 108.  As an additional control in porcine macrophage experiments, unpurified 
whole cell lysates from the same E. coli DH5α strain lacking the plasmid encoding Stx2e 
were prepared.  The endotoxin concentrations of both the purified Stx2e preparation and 
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crude lysate were determined by LAL assay as described previously (Kreeftenberg et al., 
1977).  Porcine ELISA kits for measurement of IL-1β, TNF-α, and IL-10 were purchased 
from commercial sources (Biosource/Invitrogen, Carlsbad, CA; R&D Systems, Inc., 
Minneapolis, MN).  Antibodies for magnetic cell sorting were purchased from Miltenyi 
Biotech, Inc. (Auburn, CA).  Primers and probes for qPCR were purchased from IDT 
Technologies (Corallville, IA) and the one-step qPCR master mix was purchased from 
Invitrogen (SuperScript™ III Platinum®
Vero cell assay for determination of Stx2e in blood and feces: Feces were 
collected daily from control and STEC-inoculated pigs and stored at 4
 One-Step quantitative RT-PCR System with 
ROX kit; Carlsbad, CA).   
 
o C until assayed.  
Fecal samples were prepared by high speed centrifugation with subsequent filter 
sterilization of the supernatant.  Blood samples were collected in EDTA from all pigs 
every other day beginning 2 days post-inoculation for Stx2e analysis.  Additionally, 
blood was drawn prior to euthanasia in pigs that developed neurological impairment.  All 
blood samples were centrifuged, the plasma and buffy coats removed, and RBC fractions 
were stored at 4o C until the assay was performed (within 3 days).  Stx2e concentrations 
were assessed in feces and RBC fractions using a Vero cell assay as described previously 
(Cornick et al., 2000; Gordon et al., 1992).  Briefly, samples were diluted two-fold in 
PBS and added to monolayers of Vero cells in microtiter plates.  Toxin titers were 
expressed as the log of the reciprocal of the greatest dilution that resulted in ≥ 50% Vero 
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cell death.  Specificity of the titers for Stx2e were confirmed by neutralization using a 
bovine polyclonal antibody to Stx2 as previously described (Karch et al., 1992). 
 
Cells:  Porcine monocytes were either separated from whole blood via magnetic 
cell sorting (AutoMACS) or derived from porcine peripheral blood mononuclear cells 
separated from whole blood via density centrifugation with subsequent positive selection 
of monocytes by adherence.  For both techniques, whole blood was collected from pigs in 
sodium heparin and used within two hours of collection.  Blood was diluted 1:2 in sterile 
phosphate buffered saline (PBS) and layered over Ficoll-Paque PLUS (25 ml diluted 
blood to 20 ml Ficoll; GE Healthcare, Piscataway, NJ) and centrifuged at room 
temperature for 30 minutes at 500 x g.  The mononuclear cell fraction was removed, 
placed in a sterile 50 ml conical tube, and washed in sterile PBS.   Cells were 
resuspended in PBS and counted with differential analysis using the ADVIA 120™ 
automated hematology analyzer (Siemens Healthcare Diagnostics, Deerfield, IL).  Cells 
selected via adherence were diluted in complete media (DMEM base, 10% pig serum, 
2mM L-glutamine, and antibiotic) and added to 24 well plates at a concentration of 
approximately 500,000 monocytes per well.  After 24 hours incubation at 37◦ C plus 5% 
CO2, non-adherent cells (lymphocytes) were removed, and complete media supplemented 
with 30% L929 cell media to drive differentiation into macrophages was added.  Cells 
were used on the 4th day following isolation.   For cells selected via magnetic cell sorting, 
mononuclear cells were diluted in AutoMACS buffer (Miltenyi Biotech Inc., Auburn, 
CA) at a concentration of 80 x 106 cells per ml following counting on the ADVIA 120™.   
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Mononuclear cells were incubated with anti-SWC3a antibody (BD Biosciences, San Jose, 
CA) at a concentration of 4 μg/ ml for 30 minutes at 4◦ C on a platform rocker.  Cells 
were washed twice in cold AutoMACS buffer and resuspended in 500 μl cold 
AutoMACS buffer.  Goat anti-mouse IgG MicroBeads (Miltenyi Biotech Inc.) were 
added at a concentration of 20 μl beads per 107 monocytes (based on counts from ADVIA 
120™) and incubated at 4◦ C for 15 minutes.  Cells were washed in cold AutoMACS 
buffer and diluted to a concentration of 500 μl  buffer for each 108 cells and filtered 
through a 40 micron cell strainer (BD Biosciences).  Labeled monocytes were then 
positively selected on the AutoMACS analyzer (Miltenyi Biotech Inc.) using the “Possel-
S” program.  Monocytes were then diluted in complete DMEM at added to 24 well plates 
at a concentration of 500,000 per well and differentiated into macrophages as described 
above.   
Porcine erythrocytes were collected from whole blood anticoagulated with EDTA 
and centrifuged at 1000 x g for 6 minutes at room temperature within 2 hours of 
collection.  The plasma and buffy coats were removed aseptically, and packed 
erythrocytes were washed in Hank’s balance salt solution lacking calcium, magnesium, 
and Phenol red (HBSS, Invitrogen) and re-centrifuged for 10 minutes at 1000 x g.  
Packed, washed erythrocytes were stored at 4◦ 
Transfer of erythrocyte-bound Stx2e to porcine macrophages:  Porcine 
erythrocytes (50 µl packed RBCs) were incubated with either HBSS only (negative 
control, 50 µl) or purified Stx2e (high dose 325 ng; low dose 32.5 ng) for 1 hour at room 
C for up to 3 days prior to use in 
experiments.   
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temperature.  RBCs were subsequently washed twice in HBSS and resuspended in 500 µl 
HBSS prior to addition to macrophages.   Purified Stx2e (approximately 32.5 ng) or LPS 
(approximately 3.5 ng) was added directly to some wells. After one hour of co-incubation 
with macrophages at 37◦ C/ 5% CO2, cell culture supernatants were collected and 
macrophages were washed with HBSS to remove any remaining RBC, and fresh 
complete media was added to each well.  Supernatants were collected again at 24 hours 
and stored at -80◦C prior to measurement of TNF-α levels via ELISA.   
 
Measurement of cytokine levels in plasma, tissues, and cell culture 
supernatants: Plasma was obtained from whole blood within one hour of collection and 
stored at -80◦ C until analysis.  Fresh tissues from ileum, brainstem, kidney, and liver 
were collected aseptically at necropsy and flash frozen in liquid nitrogen, with 
subsequent storage at  -80◦ C.  Tissue homogenates were prepared by suspending thawed 
tissues  in PBS (2 grams tissue per ml of PBS) and homogenizing using a high speed 
blade homogenizer (Omni TH homogenizer (Omni International, Marietta, GA)).  
Homogenates were clarified via low speed (500 x g for 10 minutes) followed by high 
speed (3000 x g for 5 minutes) centrifugation and supernatants were likewise stored at -
80◦ C prior to analysis.  Cell culture supernatants were collected from porcine 
macrophage cultures at 24 hours post treatment.  Supernatants were stored at -80◦ C and 
centrifuged prior to analysis to remove any cellular debris.   Levels of TNF-α, IL-1β, and 
IL-10 were measured using commercially available ELISA kits according to the 
manufacturer’s instructions. 
 
 
84 
RNA Isolation:  Tissues (ileum, brainstem, liver, and kidney) were collected 
aseptically at necropsy and flash frozen in liquid nitrogen.  These samples were stored at 
-80◦ 
One step quantitative real-time (qRT)-PCR: Primer and probe sequences for 
the three targets (IL-1β, TNF-α, IL-10) were taken from USDA’s Porcine Immunology 
and Nutrition database (http://199.133.11.115/fmi/iwp/cgi?-db=PINdb&-loadframes).    
One-step qRT-PCR was performed as described previously (Gallup et al., 2005).  The 
final 25 μl reaction volumes for samples included one-step master mix (SuperScript™ III 
Platinum
C until RNA isolation.  RNA was isolated as described previously (Sow et al., 2009).  
Briefly, tissue samples were partially thawed, weighed, and homogenized in 3 ml TRIzol 
reagent (Invitrogen) using an Omni TH homogenizer (Omni International, Marietta, GA). 
The samples were then further diluted in TRIzol, based on tissue weight, to obtain a 
uniform 0.0909 g tissue/ ml homogenate.  Chloroform (200 μl) was added to 
homogenates, and they were centrifuged at 12,000 x g for 10 minutes.  The aqueous 
layers were then transferred into 500 μl isopropanol, mixed, and centrifuged with 
subsequent removal of the top aqueous layer.  Pellets were washed twice in ice-cold 
ethanol, air dried, and resuspended in nuclease-free 0.1 mM EDTA.  Nucleic acid 
concentration and purity was evaluated by absorbance readings at 260 and 280 nm  
(Nanodrop™), and samples were DNase treated (TURBO DNA-free kit, Ambion. Austin, 
TX) and diluted to the same RNA concentration with nuclease-free water and RNaseOUT 
(Invitrogen) for use in one-step qPCR.    
 
® One-Step quantitative RT-PCR System with ROX kit, Invitrogen), primers 
 
 
85 
and probe (750 nM for primers and 150 nM for probes), and diluted RNA sample (6 µl).  
Thermocycling was performed with all samples run in duplicate on a GeneAMP 5700 
sequence analyzer (Applied Biosystems, Forest City, CA) under the following conditions:  
15 minutes at 55◦ C, 2 minutes at 95◦ C, and 55 cycles of 15 seconds at 95◦ C followed by 
30 seconds at 58◦ 
Clinical disease development in STEC inoculated pigs:  Seven out of the 
twenty piglets inoculated with the STEC strain developed clinical edema disease (clinical 
disease incidence of 35%).  Clinical disease was observed between days 5-10 post 
C.  Output data was then analyzed using custom Excel files 
(PREXCEL-Q™ software) with relative quantitation based on target-specific fluorescent 
signals generated during qPCR of total RNA from the whole tissue homogenates for the 
study.  Levels for each target were normalized to the total amount of mRNA per well for 
final analysis as described in detail previously (Sow et al., 2009).  
 
 
Statistical analysis:  JMP software (SAS) was used for statistical analysis. The 
distribution of all data sets were initially assessed, and data were normalized via log 
transformation when necessary.   Data were analyzed with ANOVA followed by 
Student’s t test.  Results were considered significant at a value of p<0.05.   
 
 
Results 
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inoculation (two on day 5, one on day 6, two on day 8, and two on day 10).  Six of the 
clinical pigs were discovered to have neurological signs during observation periods and 
were euthanized, the seventh pig was found dead (data not shown).  None of the piglets 
inoculated with the non-pathogenic strain developed any disease. 
 
Local and systemic Shiga toxin levels:  To correlate clinical signs and 
proinflammatory cytokine changes to Shiga toxin production and dissemination, local 
and systemic Stx levels were measured throughout the study.   Fecal Stx concentrations 
peaked at day 4 post inoculation in the STEC group.  Clinical pigs had higher levels of 
fecal Stx than subclinical pigs on all days post inoculation; the difference was statistically 
significant at days 2 and 5 post inoculation (Figure 1, p<0.05).  Five of the eight pigs 
with the highest fecal Stx concentration (Vero cell titer >65,000) developed clinical 
edema disease.  The calculated relative risk of clinical disease for pigs with the highest 
fecal Stx levels was 3.125.  Shiga toxemia was detected in 11/20 STEC inoculated pigs 
and 0/5 control pigs via Vero cell assay.  Four of the eleven pigs with detectable Shiga 
toxemia developed clinical disease.  Blood Vero cell titers ranged from 1:64 to 1:128 and 
were neutralized by specific antibody.  The relative risk of clinical disease for pigs with 
positive blood Stx titers was 1.09; therefore, the risk of clinical disease development was 
greater in pigs with high fecal Stx titers compared to those with positive blood Stx titers.  
Free fecal Shiga toxin was not detected in control pigs. 
 
Levels of IL-1β, IL-10 and TNF-α in plasma:  To assess systemic changes in 
the pro-inflammatory/anti-inflammatory responses during STEC infection, plasma TNF-
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α, IL-1β, and IL-10 were measured every other day using ELISA.  Plasma TNF-α levels 
were significantly higher in clinical pigs than subclinical pigs within the STEC group on 
day 2 post inoculation (p<0.05, Figure 2A).  This timepoint preceded clinical disease 
development by at least three days.  Levels of TNF-α and IL-1β in plasma increased over 
time in all groups, peaking at day 6-8 post inoculation (Figure 2B and 2C).  IL-10 levels 
in plasma were minimal at the time of inoculation, and were at or below detection limits 
in all three groups by day 8.  A mild rebound back to initial levels was seen at day 10 in 
both the subclinical and control groups.  There was a spike in plasma IL-10 on day 10 in 
the sole remaining clinical pig.  No significant differences in either IL-1β or IL-10 levels 
were observed between groups at any timepoint (Figure 2b and 2c).   
 
IL-1β, IL-10, and TNF-α levels in tissues: Protein levels of TNF-α, IL-1β, and 
IL-10 were measured in brainstem, ileum, liver, and kidney by ELISA to evaluate the 
local and systemic cytokine response.  Brainstem and ileum were chosen as they are the 
sites of pathologic significance in porcine edema disease, whereas liver and kidney were 
chosen to assess a more systemic inflammatory response.  TNF-α protein levels in liver 
from clinical pigs within the STEC group were significantly higher than either control or 
subclinical pigs (p<0.05, Figure 3A).  Significant differences between groups were not 
observed in TNF-α protein levels from ileum, kidney, or brainstem.  Liver IL-1β levels 
were likewise significantly higher in clinical pigs than either subclinical or control pigs, 
but a similar increase was not observed in other tissues (p<0.05, Figure 3B).  IL-10 levels 
in liver of clinical pigs were significantly higher than controls (Fig. 3C).  In contrast, IL-
10 levels in subclinical pigs were higher than either control pigs only (brainstem) or in 
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either control or clinical pigs (ileum) (p<0.05).  No significant differences between 
groups were noted in IL-10 levels in kidney.   
mRNA expression of TNF-α, IL-1β, and IL-10 was determined by one-step qRT-
PCR.  For final analysis, data were normalized to total mRNA per well.  In the liver, IL-
10 mRNA expression was significantly lower in clinical pigs than controls (Figure 4, 
p<0.05).   Significant differences in IL-1β or TNF-α mRNA expression were not 
observed in liver.  No significant differences between groups were noted in mRNA 
expression from brainstem, ileum, or kidney as determined by qRT-PCR for any of the 
three targets examined (Figure 4).   
 
Cytokine production by porcine macrophages secondary to cell-bound Stx: 
To better assess the ability of Stx2e to induce proinflammatory cytokine production in 
macrophages, we compared the capacity of Stx2e and erythrocyte-bound Stx2e to induce 
TNF-α production by porcine macrophages as determined by ELISA.  Direct addition of 
purified Stx2e to macrophage cultures resulted in a slight but insignificant difference (p 
>.05) in TNF-α at 24 hours (Figure 5).  In contrast, addition of LPS (approximately 3.5 
ng) as a positive control led to a marked and statistically significant (p<0.01) increase in 
TNF-α production at 24 hours.  Additional experiments evaluated the effect of 
erythrocyte-bound Stx2e on TNF-α production by isolate porcine macrophages to more 
closely mimic in vivo conditions.  Likewise, erythrocyte-bound Stx2e did not generate 
significant TNF-α production by porcine macrophage compared to negative control 
(Figure 5).   
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Discussion:  
The main objectives of this study were to further clarify the role of the 
proinflammatory cytokine response in clinical disease development during STEC 
infection, and to help identify the primary stimulus for any identified cytokine changes.  
A further goal was to measure systemic levels of several classical proinflammatory and 
anti-inflammatory cytokines following STEC infection to identify potential risk factors 
prior to clinical disease development.   Some of our major findings supported our 
hypothesis that clinical pigs would have a greater proinflammatory cytokine response.   
Specifically, we found that those pigs that later develop clinical disease have increased 
plasma TNF-α during the prodromal phase of STEC infection.  Additionally, clinical pigs 
had evidence of a greater systemic proinflammatory cytokine response than subclinical 
pigs, and subclinical pigs had a more substantial anti-inflammatory response in ileum and 
brainstem, tissues known to develop Stx2e-induced histologic lesions.   We also 
hypothesized that greater Stx production and dissemination would be a direct cause of 
this enhanced proinflammatory cytokine response in clinical pigs.  Interestingly, clinical 
pigs had both greater local Stx production and plasma TNF-α levels on day 2, suggesting 
a possible correlation.  To assess a more direct link between the two events, the in vitro 
studies with porcine macrophages were performed.  Based on the latter findings, 
however, a direct cause and effect between Stx production with subsequent dissemination 
and a systemic increase in TNF-α production is considered less likely.  For the in vitro 
studies, we were particularly interested in more closely mimicking in vivo conditions; 
therefore, we looked at the influence of erythrocyte-bound Stx2e on cytokine production 
by porcine macrophages.  Our results suggest that Stx2e is a less potent stimulator of 
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TNF-α production in porcine macrophages than LPS.  Previous work in the human 
monocytic cell line, THP-1, showed that Stx1 induced significant proinflammatory 
cytokine production (Harrison et al., 2004; Ramegowda and Tesh, 1996; Sakiri et al., 
1998).  The results illustrated in this study with pig macrophages suggest less of a role for 
Stx2e in proinflammatory cytokine production.  Future studies are warranted to assess the 
effects of other STEC antigens, such as flagellin, in this in vitro system.   
The plasma cytokine changes in the STEC group that occurred during the 
prodromal diarrhea phase were of particular interest, since identification of risk factors in 
the animal model might help better identify which STEC infected individuals are at 
greatest risk for HUS development.    Some risk factors, such as neutrophilia, have 
already been identified in human beings; however, additional parameters may impart 
greater sensitivity and specificity.   The findings in this study suggest that plasma TNF-α 
increases in clinical individuals prior to the onset of clinical signs; therefore, 
measurement of plasma TNF-α during the prodromal diarrhea phase of STEC infection 
could serve as a good indicator of HUS risk in human beings.  Surprisingly, plasma levels 
of both IL-1β and TNF-α increased over time in all groups, including the non-pathogenic 
control group.   One potential explanation for these findings is that the cytokine changes 
reflected in plasma are secondary to a stress of handling response.  Although pigs were 
acclimated for one week prior to inoculation, the pigs were handled more after 
inoculation, including daily collection of feces from individual pigs and blood draws 
every other day, during days 0-10 post inoculation.   
The liver findings were of particular interest, since Kupffer cells in sinusoids are 
initially exposed to antigens within the intestine.  In our pig model, it is known that Stx2e 
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is found in the circulation bound exclusively to erythrocytes, and that erythrocyte-bound 
toxin is a risk factor for clinical disease development (Matise et al., 2003).  Kupffer cells 
are also exposed to various other STEC antigens, such as LPS, which can circulate bound 
to plasma proteins (LPS binding protein) or attached to the surface of erythrocytes and 
leukocytes.   Additionally, it has been shown previously that depletion of hepatic and 
splenic macrophages in a mouse model is protective against the systemic effects of STEC 
infection (Palermo et al., 1999).  Our data provide further support for a role of the liver in 
the proinflammatory cytokine response in STEC infection.  The greater anti-
inflammatory response observed in subclinical animals could represent either a rebound 
anti-inflammatory effect following STEC infection, or alternatively, a protective effect of 
a greater anti-inflammatory response on clinical outcome.  Future studies that further 
clarify the activation status of the systemic inflammatory response antemortem, such as 
gene microarray analysis of serially collected PBMC during STEC infection, may be 
useful in determining which explanation is more accurate.   
One consideration in this data is that clinical pigs died earlier than subclinical pigs 
or controls.  Since clinical pigs were euthanized and necropsied as neurological 
symptoms arose, between 5 and 10 days post inoculation, tissues from these pigs were 
assessed at a different timepoint than subclinical and control pigs, which were euthanized 
and necropsied at 14 days post inoculation.  Thus, the argument can be made that the 
changes seen are potentially an artifact of timepoint.   It is possible that the 
proinflammatory changes seen in liver from clinical pigs are a result of the general mild 
systemic changes reflected in the plasma findings and attributed to stress of handling.  
Similarly, the anti-inflammatory changes seen in ileum and brainstem in subclinical pigs 
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may just be a general recovery response following STEC infection, and may not reflect a 
protective effect of a greater anti-inflammatory response in subclinical pigs.  We feel, 
however, that this is a less likely explanation for the following reasons.  Firstly, two of 
the clinical pigs were necropsied at day 10, a timepoint at which plasma cytokine levels 
had returned to baseline (fig. 2).  Additionally, two pigs fell ill on day 5, and although 
plasma was not taken at this timepoint, it is likely that the cytokine levels fall in between 
the day 4 and 6 values.  Consequently, only three of the seven clinical pigs were 
necropsied during the plasma TNF-α and IL-1β peak.  Finally, two of these three 
remaining pigs were necropsied at day 8, at which point plasma TNF-α and IL-1β were 
already falling in the clinical group, with no statistically significant differences between 
levels on that day and day 0.  Therefore, we conclude that the changes in TNF-α and IL-
1β protein levels in liver observed in clinical pigs are more likely a reflection of an 
increased proinflammatory response in clinical individuals.   
In conclusion, the findings of this study provide further evidence for a role of the 
systemic inflammatory response in the pathogenesis of STEC infection.  Although Stx  
itself has been found to stimulate proinflammatory cytokine production in vitro in a 
variety of cell types, the findings of this study indicate Stx2e is less efficient at eliciting 
TNF-α production by porcine macrophages than LPS.  Therefore, we conclude that Stx2e 
is likely to have a more secondary role in proinflammatory cytokine responses in porcine 
edema disease.  Finally, measurement of plasma TNF-α during the prodromal diarrhea 
phase of STEC infection may be a useful indicator of risk for systemic disease 
development.  
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Figures 
 
 
Figure 1.  Comparison of intestinal Shiga toxin (Stx) production between clinical and 
subclinical Shiga toxin-producing Escherichia coli (STEC) inoculated pigs.  Fecal 
samples were collected daily and Stx levels were analyzed by Vero cell assay.  
Specificity of titers was confirmed using specific anti-Stx antibody.  Clinical pigs had 
significantly greater Stx production than subclinical pigs on days 2 and 5 post inoculation 
(p < 0.05).   
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Figure 2.  Plasma cytokine (TNF-α, IL-1β and IL-10) levels were determined by ELISA 
in both Shiga toxin-producing Escherichia coli (STEC) inoculated and control pigs to 
assess systemic proinflammatory cytokine changes.  A. Clinical pigs within the STEC 
group had significantly higher levels of plasma TNF-α at day 2 post-inoculation (p < 
0.05).  This preceded the onset of clinical disease in pigs by 3 days. B and C. Significant 
differences between groups were not noted for IL-1β (B) or IL-10 (C).   
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Figure 2 (continued) 
B. 
0
50
100
150
200
250
300
350
400
D0 D2 D4 D6 D8 D10
Day Post Inoculation
IL
-1
B 
(p
g/
m
l)
Non-pathogenic STEC-Clinical STEC- Subclinical
 
C. 
0
5
10
15
20
25
30
35
40
45
D0 D2 D4 D6 D8 D10
Day Post Inoculation
IL
-1
0 
(p
g/
m
l)
Non-pathogenic STEC- Clinical STEC-Subclinical
 
 
 
99 
 
Figure 3.  Cytokine (TNF-α, Il-1β and IL-10) levels were measured using ELISA in 
tissue homogenates from ileum, brainstem, kidney, and liver following STEC infection.  
Clinical pigs within the Shiga toxin-producing Escherichia coli (STEC) group had 
significantly greater levels of TNF-α (A) and IL-1β (B) in liver than either subclinical 
pigs or controls (p<0.05).  Clinical pigs also had higher levels of liver IL-10 (C) than 
controls (p<0.05).  Subclinical pigs had greater levels of IL-1β in ileum than both clinical 
pigs and controls, and higher levels in brainstem than clinical pigs (B; p<0.05).   
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Figure 3 (continued) 
B. 
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Figure 4.  Relative mRNA expression for three cytokine targets (TNF-α, Il-1β and IL-10) 
in ileum, brainstem, kidney, and liver was determined using one-step quantitative real-
time PCR.   A). TNF-α mRNA expression in ileum, brainstem, kidney, and liver.  
Significant differences between groups in mRNA expression were not identified.  B). No 
differences in IL-1β mRNA expression were noted between groups in the tissues 
examined.  C).  IL-10 mRNA expression in liver was significantly lower in clinical pigs 
within the STEC group compared with controls (p < 0.05).   
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Figure 4 (continued) 
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Figure 5.  TNF-α production by porcine macrophages was measured in cell culture 
supernatants via ELISA.  Direct addition of purified Stx2e to porcine macrophages 
caused a mild increase in TNF-α (p > 0.05).  In contrast, addition of LPS produced a 
marked increase in TNF-α (**, p < 0.001).  In an attempt to more closely mimic in vivo 
conditions, porcine erythrocytes (RBC) were pre-incubated with either Hank’s balanced 
salt solution (HBSS) or Stx2e (two doses) and added to cultured macrophages.  
Erythrocyte-bound Stx2e did not result in significant TNF-α production by porcine 
macrophages.   
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Chapter 4: Role of neutrophil-bound Shiga toxin in Shiga toxin-producing 
Escherichia coli infection. 
A paper to be submitted to the journal Infection and Immunity 
S.J. Hostetter1 and N.A. Cornick
Hemolytic uremic syndrome (HUS), a systemic complication of Shiga toxin-
producing Escherichia coli (STEC) infection, is the number one cause of renal failure in 
children in the United States.  Currently, there is significant debate over how Shiga toxin 
(Stx) gets from the site of production, the intestinal lumen, to its site of action, vascular 
endothelium of the kidney, brain, and colon.  The goal of this study was to further 
characterize the role of neutrophils as a potential means of Stx transport in STEC 
infection, and to assess the ability of neutrophil-bound Stx to influence the activity of 
other cell types.  In this study we demonstrate specific binding of purified Stx2 to human 
neutrophils using flow cytometry.  Neutrophil-binding of Stx2 was further confirmed 
using Vero cell assay.  Neutrophil-bound Stx2 did not induce significant toxicity on 
cultured microvascular endothelial cells.  Proinflammatory cytokine production 
secondary to neutrophil bound Stx was then assessed in the human monocytic cell line 
THP-1.  Neutrophil-bound Stx2 caused significant IL-1β production by THP-1 cells.  
Neither purified Stx2 nor neutrophil-bound Stx2 induced significant TNF-α production 
by THP-1 cells, in contrast to LPS.  The findings of this study support a direct role for 
2 
1.  Iowa State University Department of Veterinary Pathology 
2. Iowa State University Department of Veterinary Microbiology and Preventive Medicine 
 
Abstract 
 105 
neutrophils in the binding of Stx2 and transfer to Vero cells.  Neutrophil-bound Stx2 may 
also potentiate the proinflammatory cytokine response in STEC infection through the 
generation of IL-1β by macrophages.   
 
Introduction 
Hemolytic uremic syndrome (HUS), a systemic complication of STEC infection, 
is mediated by vascular damage induced by Shiga toxemia.  HUS results in fatality in 
approximately 2-15% of individuals, and is a major cause of renal failure in those 
individuals who survive the acute infection (27).  Shiga toxins (Stxs) from Escherichia 
coli are produced initially in the gut, enter the circulation via a yet undefined mechanism, 
and cause vascular necrosis in organs that express high levels of its preferred receptor, 
globotriaosylceramide (Gb3), on vascular endothelium (kidney, brain).  Stx is a classical 
AB5 toxin, and interaction with its B binding subunits with Gb3 mediates specific binding 
followed by toxin internalization.  Once inside the cell, the inactive A subunit travels to 
the Golgi and endoplasmic reticulum via retrograde transport and is cleaved within the 
cytosol, forming an active N-glycosidase.  The active enzymatic subunit then cleaves an 
adenine from the 28S rRNA and thus inhibits protein synthesis within the cell (19).  Stx 
may also have an additional role in the pathogenesis of HUS.  Stx are capable of inducing 
proinflammatory cytokine production in a variety of cell types, including mouse  and 
human macrophages and the human monocytic cell line THP-1, and cytokines, in turn, 
greatly enhance the sensitivity of endothelial cells to the cytotoxic effects of Stx (31).  
Two major types of Stx have been described, Stx1 and Stx2.  Although the two types 
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share the same mechanism of action, they are antigenically distinct and only share 
approximately 55% amino acid homology (26).  Several variants of Stx2 have been 
described, and strains that produce Stx2 are more commonly associated with HUS than 
those that produce Stx1 or both toxin types (1).   
One key aspect of HUS pathogenesis that remains to be elucidated is how Stx 
travels from the site of production in the gut to sites of vascular damage, e.g. kidney and 
brain.  Stx binding to numerous peripheral blood elements has been reported, including 
platelets, erythrocytes and monocytes; however, most of the focus has been on Stx 
binding to neutrophils.  The first study that identified specific binding of Stx1 to human 
neutrophils used both radiolabeled Stx1 with Scatchard analysis and FITC-labeled Stx1 
with flow cytometry.  Additionally, the investigators were also able to demonstrate 
transfer of the Stx1 from the non-Gb3 receptor on neutrophils to Gb3 on glomerular 
vascular endothelial cells (28).   Further studies from the same group identified 
neutrophil-bound Stx in the peripheral blood of children with HUS, as well as healthy 
family members within the same household.  The sensitivity of the neutrophil-bound Stx 
detection assay far surpassed that of traditional methods (serology, fecal culture) at 
identifying individuals with STEC infection (29, 30).  These findings were corroborated 
by another study that identified Stx bound to human neutrophils in the blood of patients 
with HUS, even when additional evidence of STEC infection was not present (2).   
However, later studies by a different group of investigators failed to find a direct 
interaction between neutrophils and Stx1 and Stx2 (7).  Moreover, the reliability of the 
original studies was brought into question recently, when Te Loo et.al. reported that their 
initial findings were an artifact, and that no true interaction between Stx and human 
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neutrophils exists (8).  To further confound the matter, two more recent studies report 
either weak interaction between Stx and human neutrophils or interactions that are 
dependent on maturation status of neutrophils (3, 10). 
The goals of this study were to further characterize the ability of Stx2 to bind 
specifically to human neutrophils and  assess the ability of neutrophils to transfer surface-
bound Stx2 to both microvascular endothelial cells and macrophages, thereby inducing 
cell death and proinflammatory cytokine production, respectively.  The findings of this 
study support our hypothesis that human neutrophils indeed bind Stx2.  Furthermore, 
neutrophil-bound Stx2 is readily transferred to Vero cells, thereby inducing cell death.  
Finally, we show that exposure of the human monocytic cell line, THP-1, to neutrophil-
bound Stx2 may enhance IL-1β generation, but does not induce significant TNF-α 
production.  The results of this study show that neutrophils can contribute to Stx transport 
and identify a potential role for neutrophil-bound Stx in the promotion of inflammatory 
responses.   
 
Methods 
 
Shiga toxin and cell lines:  Crude Stx2 was prepared from whole cell lysate of E. 
coli strain DH5α containing a plasmid encoding the Stx2 gene as described previously 
(16, 25).  Stx2 was purified using an affinity column containing a carbohydrate analogue 
of the Stx receptor, Gb3 (17). The purified toxin was then dialyzed against PBS, filter 
sterilized, and stored at -80 degrees C until use.  Crude Stx2 lysate was used in some flow 
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cytometry experiments.  The final Stx2 concentration of the purified preparation was 
approximately 65 ng/ml (Vero cell titer 1: 131,072).  As an additional control in binding 
and transfer experiments, crude whole cell lysates from the same E. coli DH5α strain 
containing the plasmid but lacking stx2 were prepared.  Human microvascular endothelial 
cells derived from neonatal dermis (HMVECnd) were purchased from Invitrogen™ 
(Carlsbad, CA) and cultured in supplemented Medium 131 (Invitrogen™) according to 
the manufacturers guidelines.  HMVECnd were grown in either 25 cm2 flasks or 96 well 
plates pre-coated with Attachment Factor (Invitrogen™).  THP-1 cells were cultured in 
24 well plates in supplemented RPMI at a density of 1 x 106
Neutrophil isolation and toxin incubation:  Whole blood was collected from 
three healthy adult volunteers in accordance with a protocol approved by Iowa State 
University’s Institutional Review Board.  Human neutrophils were isolated from whole 
blood collected in sodium heparin following a technique Bryan Heit from the University 
of Calgary (http://www.bio.net/bionet/mm/immuno/2001-August/016695.html).  The 
majority of erythrocytes were removed via dextran sedimentation.  Briefly, whole blood 
was mixed 1:2 with 6% dextran in 0.9% sodium chloride using aseptic technique and 
incubated for one hour at room temperature.  The supernatant containing leukocytes was 
 cells per well.  They were 
induced to differentiate into macrophage-like cells by the addition of phorbol mystirate 
acetate (PMA, Sigma Aldrich®, St. Louis, MO) at a concentration of 50 ng/ml to the 
media for 48hrs.  Fresh media, lacking PMA, was added daily until cells were used in 
experiments on day 5.    
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then removed, and centrifuged at 500 x g for 10 minutes.  The supernatant was then 
removed, and remaining erythrocytes were removed via hypotonic lysis.  Mononuclear 
cells and platelets were then separated out via density centrifugation using Ficoll-Paque 
PLUS (GE Healthcare, Piscataway, NJ) according to the manufacturer’s instructions.  
The mononuclear cell layer and Ficoll layers were discarded, and the pellet was 
resuspended in Hank’s balanced salt solution (HBSS) lacking calcium, magnesium, and 
Phenol red (Invitrogen™).  Neutrophils were counted using the ADVIA® 120 automated 
hematology analyzer (Siemens Healthcare Diagnostics, Deerfield, IL).  Cell purity was 
approximately 98% neutrophils following isolation.  Neutrophils (approximately 1 x 106
Flow cytometry: Buffy coat preparations of leukocytes were made from whole 
blood collected in sodium heparin.  Whole blood was centrifuged at 500 x g for 10 
minutes.  The buffy coat and plasma were removed and added to a new 15 ml conical 
tube and centrifuged at 1000 x g for 10 minutes.  The supernatant was discarded, and 
contaminating erythrocytes (RBC) were removed via hypotonic lysis.  Neutrophils were 
isolated as described above.  Neutrophils or buffy coat leukocyte preparations were 
incubated with Stx2 (approximately 6.5 ng) or Stx2-free whole cell lysate (no toxin 
negative control) for one hour at room temperature and subsequently washed in HBSS 
 
cells) were incubated with either Stx2 (approximately 6.5 ng), LPS-rich crude whole cell 
lysate, (100 µl) or HBSS (100 µl) for one hour at room temperature immediately 
following isolation.  Cells were washed twice in HBSS and used immediately in binding 
and transfer experiments. 
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plus 2% rabbit serum. Cells were then incubated with either 10 µl polyclonal bovine anti-
Stx2 (0.20 µg), mouse monoclonal anti-Stx2 (11E10 ascites diluted 1:10, 10 µl) or non-
specific IgG (isotype control, 0.10 µg) for 30 minutes and washed in HBSS plus 2% 
rabbit serum (20).  FITC-labeled rabbit anti-bovine IgG F(ab)2 (0.15 µg) or rabbit anti-
mouse IgG F(ab)2
Neutrophil-bound Shiga toxin addition to THP-1 and HMVEC cells:  
Neutrophils were incubated with Stx2 (approximately 6.5 ng) as described above.  After 
washing twice in HBSS neutrophils were then added to established cultures of THP-1 
cells differentiated with PMA.  Neutrophils were co-incubated with THP-1 cells for 1 
hour at 37 degrees C, 5% CO
  (0.20 µg) was subsequently added to all cell suspensions for 30 
minutes.  Cells were washed and re-suspended in HBSS.  FITC fluorescence was 
evaluated on a FACScan flow cytometer and was measured with excitation and emission 
at 488 and 530 nm, respectively.  Leukocyte populations were gated separately, and 
neutrophils were selected by forward scatter and side scatter properties.   
 
Vero cell assay for Shiga-like toxin:  Stx concentrations were assessed using a 
Vero cell assay as described previously (5, 9).  Briefly, samples were diluted two-fold in 
HBSS and added to monolayers of Vero cells in microtiter plates.  Toxin titers were 
expressed as the log of the reciprocal of the greatest dilution that resulted in ≥ 50% Vero 
cell death.  Specificity of the titers for Stx2 were confirmed by neutralization using 
specific antibody as previously described (12).   
 
2, and then removed.  THP-1 cells were washed with HBSS 
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to remove any remaining neutrophils, and fresh complete media was added to each well. 
THP-1 cells were incubated for an additional 24 hrs post treatment. The assays were 
replicated a minimum of three times. 
 
ELISA for human TNF-α and IL-1β: Commercially available ELISA kits 
(R&D Systems Inc., Minneapolis, MN) were used to determine TNF-α and IL-1β 
production by THP-1 cells.  Cell culture supernatants were collected from THP-1 cultures 
at 24 hours post treatment.  Supernatants were stored at -80◦ 
Identification of specific binding of Stx to human neutrophils:  Flow 
cytometry identified specific binding of Stx2 to human neutrophils by a shift in mean 
fluorescent intensity (MFI) compared to negative controls (both isotype and no toxin 
C and centrifuged at 3000 x 
g for 5 minutes prior to analysis to remove any cellular debris.   Levels of TNF-α and IL-
1β were measured according to the manufacturer’s instructions. 
 
Statistical analysis:  JMP software (SAS) was used for statistical analysis. The 
distribution of all data sets were initially assessed, and data were normalized via log 
transformation when necessary.   Data were analyzed with ANOVA followed by 
Student’s t test.  Results were considered significant at a value of p<0.05.   
 
 
Results 
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controls were used) (Figure 1).  Specific binding to monocytes and lymphocytes was not 
identified.  Some variability in the magnitude of the shift in MFI was noted depending on 
the primary antibody used.  Likewise, neutrophil-bound Stx2 induced a significant 
increase in Vero cell toxicity compared to neutrophils only, indicating specific binding of 
Stx2 to neutrophils (p<0.001, Figure 2).  The cytotoxicity of neutrophil-bound Stx was 
abated by use of specific polyclonal antibody to Stx2.    
 
Transfer of neutrophil-bound Stx to cultured microvascular endothelial cells: 
To establish the potential role of neutrophils in the delivery and transfer of Stx2 to 
microvascular endothelial cells in vivo, the ability of neutrophils to transfer cell-bound 
Stx2 and induce toxicity in cultured microvascular endothelial cells was assessed.  
Neutrophil-bound Stx2 did not result in significant HMVECnd cytotoxicity.   
 
Effect of neutrophil-bound Stx on proinflammatory cytokine production by 
THP-1 cells:  To better understand the contribution of neutrophil-bound Stx2 to 
proinflammatory cytokine production by macrophages, the effects of neutrophil-bound 
Stx2 on TNF-α and IL-1β production by THP-1 cells was compared to that of direct 
addition of LPS or Stx2 using ELISA.  Direct addition of LPS (200 ng) resulted in a 
marked increase in TNF-α production by THP-1 cells at 24 hours (p<0.001, Figure 3A).  
In contrast, addition of purified Stx2 (6.5 ng) did not result in an increase in TNF-α 
production.  The addition of LPS plus Stx2 did not enhance TNF-α production beyond 
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that induced by LPS alone.  Likewise, neutrophil-bound Stx2 did not cause a significant 
increase in proinflammatory cytokine production (Figure 3A).   
A significant increase in IL-1β production was noted secondary to neutrophil-
bound Stx2, as well as LPS and Stx2 alone in comparison to neutrophils only (p<0.05, 
Figure 3B).  Interestingly, the magnitude of this effect was similar amongst all treatment 
groups.   
 
Discussion 
  In this study, we were able to confirm that Stx2 binds specifically to human 
neutrophils using flow cytometry.  Previous studies found a non-specific interaction 
between activated neutrophils and anti-Stx antibody caused a shift in mean fluorescent 
intensity mimicking Stx binding to neutrophils (8).  To avoid the same potential 
complication, we added an additional control (crude bacterial cell lysate lacking Stx2) to 
our flow cytometry studies to help verify the specificity of our antibody- Stx interaction.  
Additionally, we were able to verify Stx2 binding to human neutrophils using a different 
methodology, Vero cell assay.  This provides further evidence of the specificity of the 
neutrophil-Stx interaction identified in this study.  We did not identify a direct role for 
neutrophil-bound Stx2 in microvascular endothelial cell injury.  Prior treatment of 
cultured endothelial cells with LPS or proinflammatory cytokines is known to enhance 
the cytotoxicity of Stx, presumably due to upregulation of the cellular Stx receptor (6, 13, 
14, 22, 31-33, 35).  Because we were interested in dissecting out the effects of LPS and 
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Stx on host cells in this study, we looked at the cytotoxicity of Stx2 alone.  Pre-treatment 
of HMVEC with LPS and/or TNF-α may have resulted in a greater cytotoxic response.   
In this study we found less of a role for Stx2 in TNF-α production by 
macrophage-like cells than previously reported.  Based on our findings, we now speculate 
that other STEC antigens such as LPS or flagellin may play a more primary role in the 
enhanced TNF-α responses observed in STEC infection.  Previous work with human 
monocytes and the monocytic cell line THP-1 identified that purified Stx can induce both 
TNF-α and IL-1β production in vitro (23, 34).  Stx1 was found to stimulate TNF-α and 
IL-1β production in THP-1 cells in a dose and time-dependent manner.  A mild to 
moderate, yet statistically significant, increase in both cytokines was seen with a Stx1 
dose of 100 ng/ml.   A more marked response was seen with higher doses of Stx1 (400 
ng/ml) (23).  Furthermore, Stx1 affected cytokine production by THP-1 cells by 
stabilizing mRNA transcripts, thus enhancing the response.   Although Stx1 produced a 
more muted cytokine response in THP-1 cells compared with equivalent concentrations 
of LPS, the cytokine transcripts were elevated for a longer period following exposure to 
Stx1 compared with LPS (11, 24).   Similar work in human monocytes identified 
significant TNF-α and GM-CSF production secondary to higher doses of both Stx1 and 
Stx2 (18).  Although these in vitro studies indicate a potential role for Stx in the 
promotion of proinflammatory cytokine responses during STEC infection, it is difficult to 
dissect out the exact stimulus for cytokine production in vivo, where exposure to other 
potent STEC antigens such as LPS are known to occur.  Therefore, we were most 
interested in the ability of lower, more physiologically relevant levels of Stx and 
neutrophil-bound Stx to potentiate cytokine responses in an effort to more closely mimic 
 115 
what is presumed to occur in vivo.  Prior clinical studies from STEC patients found the 
maximal intestinal concentration of Stx to be approximately 20 ng/ml (Vero cell titer 
40,960), based on fecal Stx titers (4).  Based on this data, it is unlikely that Stx 
concentrations outside of the intestinal lumen, where exposure of monocytes and 
macrophages to STEC antigens would likely occur, would reach concentrations as high 
as 100 ng/ml.  The lower doses of Stx2 used here (6.5 ng/ml vs. 100-400 ng/ml) likely 
account for the disparity between our results and those previously published.  Another 
potential explanation for the lack of TNF-α response in this study could be the toxin 
preparation used.  Previous work in THP-1 cells was performed using purified Stx1, 
whereas we used Stx2.  To our knowledge, this is the first report of the effect of purified 
Stx2 on TNF-α and IL-1β production by the human monocytic cell line THP-1.   
Interestingly, both Stx2 and neutrophil-bound Stx2 enhanced IL-1β production by 
THP-1 cells.   This indicates that Stx2 is able to stimulate IL-1β production in a dose-
independent manner, since approximately 100-fold less Stx2 was present in neutrophil-
bound Stx compared with direct addition of Stx2.  Additionally, Stx2 was as potent an 
activator of IL-1β production as LPS.  Since neutrophils themselves did not stimulate IL-
1β production, it is less likely that an active neutrophil product is responsible for this 
effect. IL-1β, a potent proinflammatory cytokine, is upregulated in macrophages 
following signaling through pattern recognition receptors (PRRs) and is an important 
mediator of innate immunity.  Recently, a caspase-1 activating complex termed the 
“inflammasome” has been identified in macrophages.  Bacteria and bacterial products are 
potent activators of the inflammasome, thereby inducing IL-1β production.  Several 
pathogen associated molecular patterns (PAMPs), including LPS and flagellin, are known 
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to activate the inflammasome (15, 21).  Although no studies have been performed to date 
to implicate Stx specifically in activation of the inflammasome, it is possible that Stx 
signaling through a PRR or danger signal could mediate IL-1β production in this manner.  
Further studies that decipher the specific mechanism for IL-1β production secondary to 
Stx are warranted.   
In conclusion, the findings of this study support a potential direct role for 
neutrophils in the transport of Stx2 from the intestine to distant organs.  Additionally, 
neutrophil-bound Stx2 is readily transferred to sensitive Vero cells, thereby inducing cell 
death.  Neutrophil-Shiga toxin interactions also may potentiate the proinflammatory 
cytokine responses observed during STEC infection by contributing to IL-1β generation 
by macrophages.  Additional studies that further elucidate the mechanisms of the 
enhanced proinflammatory response associated with HUS may enable the development of 
more advanced treatment modalities.    
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Figures 
 
 
Figure 1.  Identification of Stx2 binding to neutrophils using flow cytometry.  To assess 
binding of Stx2 to human neutrophils, leukocytes were incubated with Stx2, followed by 
specific anti-Stx2 antibody and a FITC labeled secondary antibody.  Granulocytes 
(approximately 95-98% neutrophils) were gated upon based on forward and side scatter 
characteristics, and FITC fluorescence was measured.  The histogram depicts a shift in 
mean fluorescent intensity (MFI) representing specific Stx2 binding (shaded) over control 
(gray line).  Significant binding of Stx2 to lymphocyte or monocyte populations was not 
identified.  This histogram represents Stx2 binding to neutrophils as identified using 
mouse monoclonal anti-Stx2 antibody 11E10.  Smaller shifts in MFI were identified 
using a bovine polyclonal antibody.  
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Figure 2.  Binding of Stx2 to human neutrophils was assessed using Vero cell assay. 
Neutrophils were incubated with either Hank’s balanced salt solution (HBSS, negative 
control) or purified Stx2 and added to Vero cells.   Neutrophil-bound Stx2 resulted in 
significant Vero cell toxicity (*, p<0.001).  Vero cell toxicity secondary to neutrophil-
bound Stx2 was neutralized with specific antibody (data not shown).   
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Figure 3.  The ability of Stx2, LPS, co-addition of LPS and Stx2, and neutrophil-bound 
Stx2 to induce proinflammatory cytokine production in the human monocytic cell line 
THP-1 cells was assessed. A) LPS and Stx2 plus LPS induced significant TNF-α 
production in THP-1 cells (**; p<.001).  In contrast, Stx2, either added directly or bound 
to neutrophils, did not result in considerable TNF-α production by THP-1 cells .  B) THP-
1 cells released significantly more IL-1β over baseline in all treatment groups assessed (*, 
p<0.05; **, p<0.001).  
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Figure 3 (continued) 
B. 
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Chapter 5: General conclusions 
 
 
Shiga toxin-producing Escherichia coli (STEC) are a major cause of food borne 
illness in industrialized nations worldwide.  Additionally, hemolytic uremic syndrome, a 
life threatening systemic complication of STEC infection in human beings, is the leading 
cause of acute renal failure in children in the United States.  The goals of the experiments 
outlined in this thesis were to advance our understanding of HUS pathogenesis and to 
assess the efficacy of an experimental therapeutic using both in vitro studies and an 
animal model of HUS, edema disease of swine.   
The first study tested the efficacy of an oral Shiga toxin 2e (Stx2e) binding agent, 
a receptor mimic probiotic, on the incidence of clinical edema disease.  Our hypothesis 
was that treatment with the probiotic would bind and trap Stx2e within the intestinal 
lumen, thereby preventing systemic toxin absorption and subsequent clinical disease.  We 
found that although the probiotic was effective at reducing intestinal Stx2e, it failed to 
prevent systemic absorption of Stx2e.  Additionally, the probiotic did not reduce the 
incidence of clinical disease.  The conclusion from this study was that an oral Stx2e 
binding agent is less effective than parenteral specific antibody at preventing disease due 
to systemic Shiga toxemia. 
In the second study, proinflammatory cytokine responses following STEC 
challenge were assessed in pigs.  We hypothesized that pigs with clinical disease would 
have a greater proinflammatory response than subclinical pigs.  An additional goal of this 
study was to identify prodromal changes in systemic cytokine levels predictive of disease 
outcome.  We hypothesized that clinical pigs would have a greater systemic 
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proinflammatory response prior to the development of clinical signs.  Clinical pigs had 
greater levels of TNF-α and IL-1β in liver than subclinical pigs, and subclinical pigs had 
higher levels of the anti-inflammatory cytokine IL-10 in organs that develop vascular 
lesions.  Interestingly, pigs that went on to develop clinical disease had higher plasma 
TNF-α on day 2 post-inoculation, prior to clinical disease onset.  Finally, in vitro studies 
failed to identify a significant TNF-α response in porcine macrophages secondary to 
Stx2e exposure.  The conclusions from this study were that clinical pigs had evidence of 
a greater proinflammatory cytokine response than subclinical pigs, and that plasma TNF-
α may be a useful predictor of systemic disease development in STEC infected 
individuals.   
In the last study, we sought to clarify the role of human neutrophils in the binding 
and transfer of Stx2.  We hypothesized that neutrophils would bind Stx2, and that 
neutrophil-bound Stx2 would be readily transferred to other cell types.  Specifically, we 
predicted that neutrophil-bound Stx2 would be transferred to endothelial cells and 
macrophages, thereby inducing vascular necrosis and proinflammatory cytokine 
production, respectively.  The findings of this study show that neutrophils do bind 
specifically to Stx2, and that the toxin is then transferred to Vero cells.  We did not, 
however, observe significant endothelial cell toxicity secondary to neutrophil-bound 
Stx2.  Finally, neutrophil-bound Stx2 may serve to potentiate proinflammatory cytokine 
responses through macrophage-mediated IL-1β generation.   
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